GLIOBLASTOMA MULTIFORME: A META-ANALYSIS OF DRIVER GENES, CURRENT DIAGNOSIS, AND TUMOR HETEROGENEITY

*Running head

A meta-analysis of GBM driver genes

Gabriel Emilio Herrera-Oropeza^{1,2}°, Carla Angulo-Rojo³°, Santos Alberto Gástelum-López⁴, Alfredo Varela-Echavarría¹, Maribel Hernández-Rosales⁵*, and Katia Aviña-Padilla^{1,5}*

¹Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México.

²Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.

³Centro de Investigación Aplicada a la Salud, Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, México.

⁴Centro Interdisciplinario de Investigación para el Desarrollo Integral Regional, Instituto Politécnico Nacional, Guasave, Sinaloa, México.

⁵Centro de Investigación y de Estudios Avanzados del IPN, Unidad Irapuato, Guanajuato, México

* Correspondence:

Dr. Katia Aviña-Padilla katia.avinap@cinvestav.mx

Dr. Maribel Hernández-Rosales maribel.hr@cinvestav.mx

°These authors contributed equally to this work.

Abstract

Glioblastoma (GBM) is the most aggressive and common brain cancer in adults with the lowest life expectancy. The current neuro-oncology practice has incorporated genes involved in key molecular events that drive GBM tumorigenesis as biomarkers to guide diagnosis and design treatment. This study summarizes findings describing the significant heterogeneity of GBM at the transcriptional and genomic levels, emphasizing eighteen driver genes with clinical relevance. A pattern was identified fitting the stem cell model for GBM ontogenesis, with an up-regulation profile for MGMT and down-regulation for ATRX, H3F3A, TP53, and EGFR in the mesenchymal subtype. We also detected overexpression of EGFR, NES, VIM, and TP53 in the classical subtype and of MKi67 and OLIG2 genes in the proneural subtype. In keeping with this, we found a panel of nine biomarkers with a strong potential to determine the GBM molecular subtype. A unique distribution of somatic mutations was found for the young and adult population, particularly for genes related to DNA repair and chromatin remodeling, highlighting ATRX, MGMT, and IDH1. Our results also revealed that highly lesioned genes undergo differential regulation with particular biological pathways for young patients. This meta-analysis will help delineate future strategies related to the use of these molecular markers for clinical decision-making in the medical routine.

Keywords: *glioma; cancer genomics; tumor heterogeneity; diagnosis; genomic markers.*

Introduction

Glioblastoma multiforme (GBM) is the most frequent and aggressive deadly primary brain tumor in adults, accounting for approximately 82% of all malignant gliomas(1). Although it can affect children, its incidence rises with age. GBM tumors are characterized by increased cell proliferation, aggressive invasion, active angiogenesis, and a remarkable genetic heterogeneity (2). Histologically, tumors display a high morphological variability as they contain pleomorphic and multinucleated cells with high mitotic activity, show microvascular proliferation, undergo severe and characteristic endothelial hyperplasia, contain intravascular microthrombi and extensive necrosis of an ischemic or pseudoempalized nature. The multiforme denomination of GBM tumors is due to the diverse and heterogeneous microenvironments that parallel their multiple histological patterns and cytological features.

According to their ontogeny, most GBMs are primary tumors that develop de novo in the absence of previous neoplasia. Primary GBMs are highly aggressive and invasive, tend to extend to both cerebral hemispheres, or are bilateral, and they are most commonly manifested in elderly patients. Secondary GBMs, in contrast, are located in the frontal lobe and develop mainly in younger patients suffering from anaplastic astrocytoma or lowgrade astrocytoma, presenting a much better prognosis (3). Recent reports have determined that primary and secondary glioblastomas have distinct genetic alterations related to particular biological pathways (1, 3, 4), suggesting they require different therapeutic approaches. Hence, from the clinical perspective, discerning between primary and secondary GBM is highly relevant (2). Usually, primary GBMs present overexpression and gene amplification of epidermal growth factor receptor (EGFR) and mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A/p16INK4A) and phosphatase tensin homolog (PTEN) genes. Molecular biomarkers of secondary GBM include mutations in tumor protein 53 (TP53) and isocitrate dehydrogenase-1 (IDH1) genes, which correlate strongly with O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation (3, 5).

Initiation and progression of GBM tumorigenesis are related to genetic and epigenetic alterations and molecular subtypes of GBM have unique transcriptional profiles. Based on expression features, GBM tumors were originally classified into four subtypes: Neural, Proneural, Classical (proliferative), and Mesenchymal (6), a scheme that has been recently revised using transcriptomic information. The improved classification eliminates the neural subtype and considers tumors of this molecular type as containing normal brain tissue contamination (7, 8). GBM molecular subtypes are also associated with different spatial zones, heterogeneity, and aggressiveness of the tumor (9).

GBMs belonging to the proneural subtype have alterations in *TP53*, *PDGFRA*, *PIK3CA*, and *IDH1* genes (10, 12). The classical subtype, also known as a proliferative subtype, has been associated with high levels of cell proliferation and upregulation of *EGFR*(11). Mesenchymal GBMs show overexpression of mesenchymal and astrocytic markers (*CD44*, and *MERTK*) and down-regulation of neurofibromatosis type-1 (NF1) and upregulation of chitinase 3 like 1 (*CHI3L1/YKL-40*) and *MET* genes are frequently observed (10). While the proneural subtype has been mostly reported in younger patients and is associated with a favorable prognosis, the mesenchymal and the classical subtypes are usually linked to more aggressive high-grade gliomas that appear in adult or elderly life.

Recent advances employing Next Generation Sequencing have led to a better insight into the molecular biology of gliomas contributing potential markers for better diagnosis, and new approaches to finding specific treatment strategies (13). GBM remains an incurable deadly disease with an abysmal prognosis that has not significantly shown improvement, causing an enormous individual and societal burden. Thus, there is a need for tumor-specific drug targets and pharmacological agents to inhibit cell migration, dispersal, and angiogenesis (7).

GBM heterogeneity makes this type of cancer one of the most challenging to treat and consists of *inter-tumor* and *intra-tumor* feature variations. Inter-tumor heterogeneity refers to GBMs from different patients with altered and differing genotypes and phenotypes related to diverse etiological and environmental factors. On the other hand, intra-tumor

heterogeneity refers to the presence of multiple and different cell subpopulations within the same tumor, defining its topology and architecture (14). The comprehensive genomic classification of GBM paves the way for an improved understanding of GBM, which in the future may result in personalized therapy. Hence, there is an urgent need to further our knowledge of tumor heterogeneity as it will help design better therapies against GBM and tumor recurrence.

Based on a meta-analysis, in this study, we describe the heterogeneity of GBM at the transcriptional and genomic levels, with emphasis on driver genes currently used as genomic markers. For that purpose, from sixty clinical reports, we selected and analyzed eighteen driver genes that have shown deregulated behavior in patient samples. Using bioinformatics pipelines, we examined their mRNA expression in the different GBM molecular subtypes and the presence of somatic mutations linked to possible disruption of protein function. We hope that the new knowledge generated in this study leads to novel therapeutic intervention strategies.

Materials and methods

Data mining and selection of GBM driver genes currently used as genomic markers in the clinic

Literature research was performed using a systematic approach to identify GBM biomarkers in the routine clinical diagnosis that yielded differential transcriptomics or genomic profiles on tumor samples. Using a combination of three terms (1) "Glioblastoma", (2) "Clinical", and (3) "Case", a total of 3,238 clinical reports were found using the BVS (1548), Cochrane (0), Karger (271), and PubMed (1419) databases. Clinical reports were identified and selected by title and summary. All articles were evaluated using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (http://prisma-statement.org/) to determine their eligibility, resulting in sixty reports, as described in Suppl. Material File 1. The search was conducted in July 2020 and focused on studies published in June 2000 – June 2020.

Data source for the gene expression analysis

Eighteen genes were found to be involved in GBM diagnosis during the neuro-oncology clinical routine and evaluated for their mRNA expression analysis using data from the Glioblastoma BioDiscovery Portal (GBM-BioDP) https://gbm-biodp.nci.nih.gov (15). The gene expression data includes normalized (level 3) data from Verhaak 840 Core, a filtered data set conformed of three microarray platforms: HT_HG-U133A (488 patient samples/612042 features), HuEx-1_0-st-v2 (437 patient samples /618631), and AgilentG4502A_07_1/2 (101+396 patient samples /617813). GBM molecular subtypes were assigned according to the Verhaak classification (12).

Determination of gene expression of GBM driver genes

We classified the mRNA expression analysis of the driver genes according to their biological ontology into three groups: 1) DNA repair and chromatin remodeling, 2)

Cytoskeleton and cellular proliferation, and 3) Tumor suppressors genes. Using Python scripts (https://github.com/kap8416/GBM-META-ANALYSIS-OF-DRIVER-GENES), we determined the average and standard deviation of the z-score expression values for all patient results and classified them into the molecular GBM subtypes (Classic, Proneural, Mesenchymal, and Neural), and grouped them by their corresponding biological gene ontology group. Although the Neural subtype was eliminated in the improved classification, we included it in this study and considered it as normal tissue.

We examined the mRNA expression patterns of the driver genes clustered by patient subgroups taking their age into account. Three subgroups were created: 10-29-year-old patients (young subgroup), 30-59-years-old (adult subgroup), and 60-89-years-old (elderly subgroup). The average of the z-score values among the patient subgroups was clustered into the molecular GBM subtypes.

Finally, the Mann-Whitney test was used to examine the statistical difference in the mRNA expression z-scores between GBM molecular subtypes and patient subgroups and between each gene and GBM subtypes. Statistical significance for the test was set to p < 0.05.

Data source for somatic mutations of GBM

Genomic data for the eighteen genes previously identified as molecular markers was downloaded from the NIH website https://portal.gdc.cancer.gov/ using the following restriction criteria: Primary site: brain; Program: TCGA; Project: TCGA-GB; Disease Type: gliomas; Sample type: primary tumor; Clinical age of diagnosis: 10-29 years, 30-59 years, and 60-89 years.

Determination of mutations in GBM and driver genes

Using Python scripts (https://github.com/kap8416/GBM-META-ANALYSIS-OF-DRIVER-GENES), the number of mutations per gene in the TCGA-GBM project was determined

by calculating the amount of different genomic DNA changes reported in each gene. Subsequently, the relative percentage of mutations per chromosome was calculated by taking into account the length and the number of coding genes of the respective chromosome. Substitutions, deletions, and insertions were identified, then the number of nucleotide changes occurring in all genes was determined, and their distribution was compared to the distribution of those present in the driver genes. Moreover, the total number of mutations per gene and the genome location of the somatic mutations were compared among patient subgroups according to their age. Finally, the protein phenotype impact values (polyphen) of all the canonical missense variant consequences of the driver genes in the TCGA GBM project were determined, analyzed, and compared between patient subgroups clustered by age.

Functional enrichment for driver genes, unique or shared pathways

GO enrichment analysis was performed using the Metascape tool (http://metascape.org/). We then used the meta-analysis workflow to compare the driver gene pathways with those of the highly mutated genes to identify unique or shared biological pathways in which they are involved. Using Python scripts the top fifty mutated genes observed in the TCGA-GBM project were clustered by age group. Those genes were selected and analyzed by their GO enriched terms. Finally, affected genes in their protein polymorphism phenotype with >3 probably damaging consequences (PR) were clustered by the patient subgroups for the GO terms and TRRUST enrichment analysis.

Results

Identification of GBM driver genes as genomic markers in the clinic

Sixty clinical reports were found from 2005 to 2020 that were fully-text reviewed. A total of 73 patients with GBM were characterized and described in Table 1. Patient demographics consisted of 43 men and 30 women with ages ranging from four to seventy-eight years and a mean age of 43.31. Twenty-two patients were classified as young (4-29 years), thirty as adults (30-59 years), and twenty-one as elderly (60-78 years).

Patients underwent a biopsy procedure to evaluate the expression and mutations of biomarkers, which were the most representative genes used in clinical cases over the last fifteen years. More than 80% of the clinical cases highlighted the use of a combination of two to eleven of the eighteen genomic markers. The most-reported were *IDH1*, *GFAP*, *MKi67*, and *MGMT*, followed by *TP53*, *ATRX*, and *EGFR*.

In this meta-analysis, only the biomarkers with differential positive results for patient diagnosis in the clinical reports were selected for further analysis (Table 1). According to their Biological Process Gene Ontology, driver genes were clustered using k-means into three groups to determine their possible role in common pathways. The first group includes ATRX, H3F3A, IDH1, MGTM, and TERT driver genes related to DNA repair and involved in chromatin remodeling pathways. The second group includes the cytoskeleton and cellular proliferation-related genes EGFR, FLT1/(VEGFR), BRAF, GFAP, MKi67, NES, OLIG2, PIK3CA, SMAD3, S1001A, and VIM. In particular, EGFR has an essential role in activating the receptor tyrosine kinase/Ras/phosphoinositide3-kinase RTK/RAS/PI3K pathway. Alterations in this pathway disrupt the G1-S transition in the cell cycle, which is highly relevant in the progression and excessive proliferation of GBM tumor cells. The third group included tumor suppressor genes SMARCB1/INI1 and TP53 which are negative regulators of cell growth control, normally acting to inhibit tumor development.

Differential expression meta-analysis of driver genes of GBM tumorigenesis

Due to the high inter- and intratumor heterogeneity in GBM and to gain insight into this complex process, the expression profiling pattern of the top eighteen genes used as biomarkers in the clinical report meta-analysis was analyzed using gene expression data from the Glioblastoma BioDiscovery Portal. We focused on this analysis according to the Verhaak molecular classification of GBM, which groups tumors as neural, proneural, classical, and mesenchymal (12). Although an improved classification recommends no to include the neural subtype, we decided to use it as reference of non or low-proliferative tissue, also denominated as normal tissue as it derives from the PBZ (peripheral brain zone)(14). The gene expression analysis included all data available from the GBM-BioDP, including 370 samples for *NES* and *OLIG2* genes, 270 samples for *EGFR* gene, and 197 samples for the other driver genes (Table 2).

First, we analyzed the overall profile expression pattern of each gene among GBM subtypes (Table 2). For the DNA repair and chromatin remodeling genes, such as *ATRX* and *H3F3A*, we observed a tendency to a lower expression level in mesenchymal and an increased expression in proneural compared to neural and classic subtypes. An inverse pattern was observed for *MGMT* with a tendency to be up-regulated in mesenchymal and down-regulated in proneural subtypes with respect to neural and classic subtypes. The *IDH1* gene showed a different pattern for the classical subtype, as it is highly expressed compared to neural, proneural, and mesenchymal subtypes. No changes for *TERT* expression were found.

Among the cytoskeleton and cellular proliferation genes, the most substantial differences among subtypes are for *EGFR*, with a general tendency to be up-regulated in the classical proliferative subtype and down-regulated in the proneural and mesenchymal subtypes. Another tyrosine kinase growth factor, *FLT1*, did not show differences in expression among GBM subtypes. The downstream effectors for growth factors *PIK3CA* and *SMAD3* showed up-regulation and down-regulation, respectively, for the proneural subtype; meanwhile, for the classical and mesenchymal subtype *SMAD3* showed a tendency to

up-regulation. Another proliferation biomarker, *MKI67*, showed a marked overexpression in the proneural subtype and a tendency to down-regulation in the neural, classical, and mesenchymal subtypes. *NES* and *VIM* appeared to be expressed more in the classic subtype than in other subtypes. Moreover, no relevant changes were observed for *GFAP*, another intermediate filament expressed in neural stem cells, *OLIG2* is up-regulated in the proneural and down-regulated in the mesenchymal subtypes, and *S100A1* was found to be up-regulated in the proneural subtype. For the tumor suppressor genes, *TP53* is clearly down-regulated in the mesenchymal and, to a lesser degree in the classical subtype, but up-regulated in the less proliferative proneural subtype. In contrast, *SMARCB1* showed a different pattern, being overexpressed only in the classical subtype.

We then analyzed the expression patterns of the driver genes clustered into three subgroups of patients according to their age (Tables 3-5). An important observation is that among tumors showing expression of these genes in patients under 30 years, the neural and mesenchymal subtypes were not observed (Table 3). On the other hand, the driver gene expression in the mesenchymal subtype is only present in patients older than 80 years (Supplementary Figure 1).

For the young subgroup, the samples were determined to belong only to proneural and classical subtypes, and from the 18 genes analyzed, only *OLIG2* and *VIM* showed a differential pattern in gene expression. *OLIG2* is up-regulated in the proneural tumors, according to its role as a differentiation biomarker. Meanwhile, it revealed a down-regulation tendency in the classical subtype. An inverse pattern is observed for *VIM*, which is down-regulated in proneural and up-regulated in the classical subtype. Interestingly, *EGFR* is down-regulated in both subtypes (Table 3).

Among the subgroup of adult patients, the behavior of the *EGFR* gene stands out as it is up-regulated in the classic subtype and down-regulated in proneural and mesenchymal subtypes (Table 4). The same pattern was observed in the elderly subgroup, but with a bigger gap between subtypes (Table 5). Analyses of genes *ATRX*, *H3F3A*, *MGMT*, *MKi67*, *NES*, *OLIG2*, *S100A1*, *VIM*, *SMARCB1*, and *TP53* in the adult and elderly patients

(Table 4, Table 5), revealed the same pattern in the expression changes among subtypes as observed in the overall analysis.

To analyze the variation of these biomarkers at different stages of life in each subtype, we selected the genes with the most remarkable differential expression pattern. The most common GBM biomarker, *EGFR* gene, showed a remarkable up-regulation in the classic subtype from adult to elderly subgroups, while it was down-regulated in the young subgroup. An inverse pattern is observed in the proneural subtype, with progressive down-regulation from young to adult and elderly subgroups (Figure 1a). For *BRAF*, a differential pattern was observed only in the proneural subtype, being up-regulated in tumors in young patients and down-regulated in elderly patients (Figure 1b). *OLIG2* had a remarkable differential pattern in the classical subtype, in which it is down-regulated in young patients and shows an up-regulation in elderly patients (Figure 1c). *IDH1* expression varies in the classical subtype, being down-regulated in young patients and up-regulated in both adult and elderly patients (Figure 1d). Finally, *GFAP* and *VIM* also showed a variation in expression among the classical subtype samples, but it was of a minimal magnitude (Figure 1e and 1f).

Summarizing, the gene expression analysis showed that the altered expression pattern in the mesenchymal subtype include overexpression of *MGMT* that contributes to mutation development, and down-regulation of differentiation biomarkers as *OLIG2* but up-regulation of stemness biomarkers as *VIM*. The altered expression profile in classical subtype includes overexpression of proliferation biomarkers like *EGFR* and stemness biomarkers as *NES* and *VIM*. The expression profile in proneural showed more characteristics of neural progenitor with the up-regulation of *OLIG2* (Table 6).

Somatic Mutation analysis on driver genes

Gene mutation profiling has also served as a biomarker for the diagnosis and treatment of GBM. We used high-throughput data from the TCGA-GBM project and obtained the genomic profiles of a total of 588 clinical cases.

Among the driver genes, clinical cases showed that most frequently affected genes in patients were *TP53* (26%), *EGFR* (22%), *ATRX / PIK3CA* (~10%), and *IDH1 / MKi67* (~5%) (Suppl. Figure 2). For an overall view of GBM aberrations, the distribution of the total mutated genes and their DNA changes was determined using the relative percentage of gene mutations according to gene length and number per chromosome. Even though they are not the chromosomes with the highest number of genes, chromosomes 15, 14, and 21 showed the highest percentage of mutations. The lowest percentage was found in chromosomes 18, 10, and Y (Figure 2a). Chromosome 1, which contains the highest number of coding genes (2076), showed a lower percentage of mutations than chromosome 17, which contains less than 60% number of genes (1209). *TP53* (17p13.1), which suffers from a broad amount of mutations, and *GFAP* (17q21.31), two of the top used genomic markers for their importance due to their genetic alterations, are found in this chromosome (Figure 2b). Among all mutations, 95% substitutions, 3% deletions, and 2% insertions were identified (Figure 2a).

A comparison was established to infer whether the total distribution of DNA changes present in all genome-wide mutations was conserved in driver genes, resulting in an affirmative outcome, where DNA changes of nucleotides G-C were the highest (Figure 2c). However, mutations in the driver genes displayed a higher number of deletions and insertions than the whole-genome rates.

The genome location and frequency of gene mutations were determined according to the patient age subgroup. Chromosome 15 showed the highest percentage of mutations in all subgroups. However, some chromosomes, such as 6, 13 and X, showed different patterns according to patient age. Regarding mutation types, substitutions were the highest in all patients, but an increase of deletions and insertions was found according to patient age (Figure 3a). We also observed that mutations in the driver genes reflect the parallel distribution of the genome-wide mutations (Figure 3b), as it is the case in other cancers (16). However, the frequency of mutations varies according to age group, highlighting the different mutational behavior of driver genes in the young subgroup. In

particular, *TP53* and *EGFR*, which show to be the most mutated genes in adult and elderly subgroups, are not mutated in the young subgroup, where *ATRX* is the most affected driver gene. Among other DNA repair and chromatin remodeling genes, the mutation frequency behavior of *IDH1*, and *MGMT* increases at 30 years of age and decreases at 60 years (Figure 3b). When analyzing these mutations in more detail, we observed that most of the mutations in all subgroups are substitutions: 91% in young, 80% in adults, and 87% in the elderly.

Summarizing, the *TP53* tumor suppressor gene was found to have the highest frequency of mutations among all patient groups. For *SMARCB1*, another tumor suppressor gene, we found few mutations in adult and elderly subgroups, and none for the young subgroup (Figure 3b).

Phenotypic consequences of mutations on driver genes

We also studied the phenotypic consequences of each mutation, which can often cause many of them. In the case of *TP53*, for example, a single mutation affects its 27 transcripts, causing consequences of different types. The missense variant consequence appears to be by far the most abundant, representing 47% of all consequences elicited by somatic mutations. Downstream and upstream gene variants, frameshift and intron variants, and stop gain, represent 35% of the consequences caused by mutations, and the remaining percentage is distributed among all other consequences.

Then, we focused on analyzing the biological relevance of mutations on the driver genes. Polymorphism Phenotyping (polyphen) helps to predict the functional significance of an allele replacement from its features by a Naïve Bayes classifier (17). The polyphen impact reported in TCGA is a prediction of a mutation consequence being probably damaging, possibly damaging, or benign. Therefore, we used this data to indicate the possible impact of the consequence types on the function of the proteins encoded by the driver

genes. As we found that polyphen impact was mainly reported for the missense variant consequence, we focused on the possible impact of amino acid substitutions.

Driver gene mutations were clustered by patient age and analyzed by their protein phenotype impact values. Among the driver genes, the most affected among all patient samples were *TP53*, *EGFR*, *ATRX*, *PIK3CA*, *IDH1* and *MKi67* (Figure 4). Mutations in the tumor suppressor gene *TP53* represent one of the most common genetic lesions in cancer. In keeping with this, *TP53* was the most affected gene among the driver genes and in the whole genome, increasing abruptly with patient age, as was the case for *EGFR*. In this clinical cohort, among the DNA repair and chromatin remodeling genes, *MGMT*, and *H3F3A* mutations were present only in the young and adult subgroups, with no possible negative impact on their protein functions. In *FLT1*, *BRAF*, and *MIK167*, the polyphen impact indicates damage in protein functions for the adult subgroup. *NES* and *VIM* mutations are present only among patients below 60 years of age with an unfavorable consequence in protein structure and function. For the *GFAP* and *S1001A* genes, no mutation rates for protein polyphen impact were found. Notably, *OLIG2* mutations with damaging impact consequences were found only in the elderly subgroup.

Driver gene biological pathways compared to the highest affected genes in GBM

Functional enrichment analysis was carried out for driver genes and for other genes identified with the worst protein polyphen impact. Driver genes are significantly enriched in hsa:0513 and hsa:0512 for pancreatic and endometrial cancer from the KEGG pathway (-log 10, 9.05> -7.3), and the top GO terms include dsRNA processing, multicellular organism growth, negative regulation of cell differentiation, regulation of DNA metabolic process, and regulation of neuron apoptotic process (-log10 -7.3>-4.80) (Figure 5a). We also observed that the most affected protein phenotypes are functionally enriched in biological processes such as blood circulation, purine containing compound biosynthetic process, cellular response to nitrogen compound, and vascular process in the circulatory system (-log10 -30.02< -22.68) (Figure 5b). The biological pathways enriched were Reactome has R-HSA-382551: Transport of small molecules, (-log10 -46.69), has KEGG

has:04022 cGMP PKG signaling pathway, has: in has:0513 and 00071 Fatty acid degradation, and has:00010 Glycolysis/gluconeogenesis pathways (-log10 -39.80 > -16.74) (Figure 5b). Those lesioned genes were linked to seizures, epilepsy, weight loss, pediatric failure to thrive, mental depression, irritation, and vomiting symptoms (-log10 -18< -8.3) (Figure 5b).

Discussion

Current clinical standard methods in neuro-oncology for GBM diagnosis consist of tumor surgery resection and biopsy followed by pathology analysis. We searched literature over the last vicennium and found sixty clinical reports of seventy-three clinical cases in which patient tumor biopsy or fluid sample underwent the analysis of a combination of genomic biomarkers which mainly consisted in IDH1, GFAP, MKi67, and MGMT coupled in sets with more than two and up to eleven additional markers per sample for diagnosis. Genomic markers were reported for their relevance as measurable indicators of the presence and severity of GBM. Among those genes, the measures on the expression of ATRX, MGMT, FLT1, GFAP, MKi67, NES, OLIG2, S1001A, VIM, PIK3CA, as well as the genetic analysis of driver mutation events in BRAF, H3F3A, TERT, EGFR, IDH1, SMAD3, TP53, and SMARCB1 were highlighted from our literature search strategy. We searched among clinical results for a pattern of biomarker behavior in the analyzed samples with unsuccessful results. Aware of inter-tumor molecular heterogeneity as a significant challenge, and due to the remarkable importance of driver genes for the routine clinical role, we delved into their biological behavior. A compendium of summarized findings of driver genes is shown in Table 6.

GBM inter-tumor heterogeneity allows molecular subclassification based on genomic profiling. This is also affected by intra-tumor heterogeneity, originating from two proposed mechanisms, clonal evolution, and cancer stem cells. Clonal evolution is the process by which a single cell undergoes reiterative genetic changes which allows it to evolve and disseminate, forming a tumor (18). In contrast, cancer stem cells in GBM could possess different stemness according to their cellular ontology, being a direct transformation from a normal stem cell or a reprogramming process from a cancer stem cell with less proliferative or differentiation capacity (15). The GBM tumor consists of a core region of high cell proliferation and inflammation, delimited by a margin between the tumor tissue and the normal brain cells, and then the PBZ mainly composed of normal tissue with some infiltrative and isolated tumor cells (14).

Based on a meta-analysis, we herein describe the heterogeneity of GBM at the transcriptional and the genomic levels, with an emphasis on tumorigenesis driver genes currently used in the clinic as genomic markers. Altogether, our results suggest that a combination of these biomarkers would provide a multidimensional approach for a better diagnosis and GBM subtype molecular classification for patient prognosis. Besides, our studies for gene expression and somatic mutations will provide information on the heterogeneity of primary GBM types due to their clinical relevance.

Our meta-analysis from mRNA expression data agrees with previous reports with respect to the mesenchymal subtype. This subtype is characterized by its poor prognosis, stem cell biomarkers, angiogenesis, a prominent radio, and chemoresistance. From the eighteen genes analyzed, we found up-regulation of *MGMT*, which may be related to its own promoter's unmethylated status frequently observed in this GBM subtype and related to Temozolomide treatment resistance and short patient survival (19). In our analysis, this expression profile was conserved during adult and elderly life stages.

Furthermore, the down-regulation of *ATRX*, *H3F3A*, and *EGFR* was observed. *ATRX* encodes an adaptor protein that contributes to the Methyl-CpG binding protein 2 (*MeCP2*) mediated pericentric heterochromatin organization, which is very important for neural differentiation (20); thus, down-regulation of this gene might be expected in a less differentiated subtype with more stemness such as the mesenchymal GBM subtype cells. The opposite, up-regulated behavior, was observed in the proneural subtype, which has less stemness and more characteristics of a differentiated cell. Another chromatin remodeler, *H3F3A*, whose driver mutations HK27M and G34R induce dysfunction of Polycomb repressive complex 2 (*PRC2*) and dramatic alterations of gene expression (21, 22), may contribute to high alterations in profile expression for mesenchymal GBM subtype. *EGFR*, which is perhaps one of the best-characterized molecules in primary GBM (23), showed a down-regulation in mesenchymal and proneural subtypes, but a clear up-regulation in the classical GBM subtype. This behavior is conserved across all age groups and strikingly marked for the elderly population. This expression profile could be dependent on mesenchymal GBM increased mutation rates, which may play a

feedback role downregulating *EGFR* gene expression. Co-existence of mutations in critical molecules from downstream *EGFR* signaling such as Ras or *PTEN*, which maintain active signaling without a ligand to the receptor, could play a role as an alternative mechanism.

We observed other genes with striking profile expression, including *NES*, *VIM*, and *TP53*, with up-regulation behavior. *NES* and *VIM* encode the intermediate filament proteins Nestin and Vimentin. Vimentin is expressed mainly in mesenchymal cell types, while Nestin mainly in neural stem and progenitor cells in the central nervous system (24). These proteins function not only as part of the cytoskeleton, but also impact several key cellular processes such as proliferation, death, migration, and invasiveness (24). Our analysis showed that *VIM* is up-regulated in both mesenchymal and classical GBM subtypes and *NES* only in the classical subtype. This pattern may be related to the ontogenesis of these tumors and suggest the transition state for classical GBM to a possible mesenchymal GBM, but with a neural stem cell marker remaining.

The proneural GBM subtype showed up-regulation of *MKI67* and *OLIG2*. *MKI67* encodes the DNA binding protein Ki-67 and is widely used as a proliferation marker as it participates in chromosome motility and chromatin organization during the cell cycle (25). *OLIG2* encodes a central nervous system transcription factor that plays an essential role in the proliferation of oligodendrocyte precursors and their differentiation (26). *OLIG2* also showed down-regulation in classical and mesenchymal GBM subtypes. Therefore, these expression patterns support the idea that the proneural GBM subtype arises from central nervous system progenitors with fewer stemness properties but with proliferative capacity.

Our analysis in the expression profile for the eighteen driver genes supports the GBM ontogenesis hypothesis from Celiku *et al.* 2014 (15), which proposes that proneural subtypes can be generated from neural progenitors, and these cells may gain somatic mutations to become classical and consecutively mesenchymal subtypes. It is also

possible that classical or mesenchymal subtypes originate from central nervous system progenitors with high stemness.

In this study, we found that all driver genes have reported mutations in GBM patients. However, genes that are significantly mutated and that display multiple biological consequences include *TP53*, *ATRX*, *PIK3CA*, and *EGFR*. Abnormalities of the *TP53* gene have been the most extensively investigated genetic variations found in more than 50% of human tumors (28). Contrary to other reports where *TP53* mutations are more related to pediatric tumors (29), we found an increasing behavior from the young to elderly subgroups. The same behavior is observed for genes *ATRX*, *PIK3CA*, and *EGFR*. However, *TP53* and *EGFR* were found to be the most mutated genes in adult and elderly subgroups, while these mutational behavior changes in the young subgroup, where *ATRX* is the most affected gene (Figure 4b).

Impairment of the DNA repair process is expected to increase the overall frequency of mutations and, hence, the likelihood of cancer-causing mutations. In comparison to other studies in which *ATRX* is mutated only rarely in adult primary GBM, but frequently found in younger adults with lower-grade glioma (WHO grade II/III)(30), we found a high frequency at 30 years that decreases in elderly patients. Similar behavior was identified for *IDH1* and *MGMT* DNA repair and chromatin remodeling genes.

Additionally, *NES* and *VIM* mutations were absent in the elderly subgroup and are present only in patients below 60 years-old with an unfavorable consequence in protein structure and function. In contrast, *OLIG2* mutations with negative impact consequences were found only in the elderly patient subgroup.

Some driver mutations on key genes have been pivotal for the diagnosis and prognosis of GBM patients. We focused particularly on the effects of mutations with non-synonymous changes, also called missense mutations, which alter the codons so that they specify different amino acids during protein synthesis (Suppl. Figure. 3), and carried out a comparison of GO enriched terms of the selected driver genes with the genes

identified with a higher probability of damaging consequences. We found that highly affected pathways such as blood circulation and vascular processes in the circulatory system are consistent with alterations in angiogenesis in GBM. We also identified a link of the lesioned proteins to seizures, epilepsy, weight loss, pediatric failure to thrive, mental depression, irritation, and vomiting, among other symptoms which are in agreement with those reported in the clinical cases reviewed.

Efforts have been made for the identification of relevant biomarkers to assess GBM progression by targeting genes with the highest density of missense mutations. For example, tumors with the *BRAF* V600E mutation tend to be more severe. This somatic mutation prevents *Braf* protein from controlling cell proliferation (Suppl. Figure 3), which has been reported in the TCGA database, appearing at all ages but more frequently in elderly patients.

TP53 mutations were predominantly point mutations, which lead to amino acid substitutions in the DNA binding domain (DBD). The substitution of arginine residues within the DBD, such as R175, R248, and R273, was reported in other studies and was also found in the GBM patients (31). However, this was not the most abundant amino acid substitution, being G105R, S127Y, P152S, and V157G, examples of some amino acid changes abundantly reported in the TCGA cohort.

The most cited biomarker for diagnosis *IDH1* R132H has also been reported in the TCGA database as a mutation in all age subgroups with a negative polyphen impact (3). On the other hand, the H3K27M mutation that has been highly linked to pediatric thalamic gliomas and is associated with a worse prognosis than low-grade tumors was not found in the TCGA cohort, which is the case of other biomarkers used in clinical studies, such as H3G34R, H3G34N, *EGFR* R776C, and the *TERT* promoter mutations C228T and C250T (21, 22, 30).

To better understand the behavior of mutations in young patients, we briefly analyzed genes that are involved in GBM with the worst polyphen impact consequences and

analyzed the transcription factors that regulate them. Our results showed that the young subgroup behaves differently, as genes that are mutated are regulated by different TFs. Moreover, the TFs that regulate genes with mutations in the young subgroup share almost no TFs with adult and elderly subgroups. This might explain why the young subgroup has a divergent behavior in comparison with the other subgroups. On the other hand, the adult and elderly subgroups share most of the biological pathways, while microtubule cytoskeleton organization, regulation of microtubule based process, adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling among others are GO terms unique for the adult subgroup, whilst protein-protein interactions at synapses, regulation of cyclase activity and carbohydrate digestion and absorption are unique functional terms for the eldery subgroup. In particular, genes with mutations with a negative polyphen impact in the 10-29-year-old subgroup share fewer identities with the 60-89 year-old subgroup (Suppl. Figure 4).

It is surprising that among all the TCGA data reported for GBM, several mutations that are defined as biomarkers could not be found. The absence of a clearly defined and concordant pattern between clinical, transcriptomics, and mutational dynamics studies, support the idea of outstanding heterogeneity in GBM. Despite the high abundance of somatic aberrations in GBM tumors, only a select few have been associated with clinical relevance and are currently used as biomarkers. No single mutation has been identified to trigger a particular type of GBM tumor. The intra and inter tumor heterogeneity of GBM has revealed its "multiforme" nature not only at its morphologic and phenotypic levels but also on its genotype.

Furthermore, the relationship between genetic alterations and gene expression at the mRNA level is not always linear. The interplay between distant genetic interactions and epigenetic changes also have a significant impact on the expression of specific genes. Hence, the selection of the most commonly mutated and amplified genes as therapeutic targets may not be sufficient. Our results showed that the link of genomic markers and profile expression with their phenotypic alterations is more complex than previously thought. With this analysis, however, we expect to contribute to the construction of a panel

of driver genes to better delineate the intra- and inter-tumor heterogeneity for a more accurate diagnosis. To achieve this objective, it is crucial to analyze the raw data for other key molecules involved in the mechanisms that drive the balance between proliferation and differentiation in the stem and cell precursors for the central nervous system.

Currently expression levels of *ATRX*, *MGMT*, *FLT1*, *GFAP*, *MKi67*, *NES*, *OLIG2*, *S1001A*, *VIM*, and *PIK3CA* are used in the clinic for patient GBM diagnosis and prognosis. Our results suggest that the biomarker set integrated by *ATRX*, *H3F3A*, *TP53*, *EGFR*, *NES*, *VIM*, *Mki67*, *MGMT* and *OLIG2* genes could be a strong combination to determine the GBM molecular subtype (Figure 6). For example, the mesenchymal subtype, known as the most aggressive GBM, showed overexpression of *MGMT* and the repression of *ATRX*, *H3F3A*, *TP53*, and *EGFR*. On the other hand, while overexpression of *EGFR*, *NES*, *VIM*, and *TP53* was characteristic of the proliferative or classical subtype, if there is overexpression of *Mki67* and *OLIG2*, the prognosis could be more favorable owing to their association with the less aggressive proneural subtype (Figure 6). Further clinical trials with patient samples for expression analysis using the abovementioned biomarkers could provide confirmatory evidence for their clinical potential.

Conclusions

GBM is a highly heterogeneous cancer that consists of multiple molecular alterations. Despite the vertiginous advances in the clinical medical area, the prognosis of patients continues to be unfavorable, with an average of overall survival of less than one year. The differential molecular characteristics of histologically similar tumors make it difficult to predict clinical outcomes and select optimal treatment strategies. Given the heterogeneity of GBM and the multitude of factors that influence disease progression, general clinical characteristics are insufficient to predict individual prognosis and survival accurately. In clinical routine, a combination of biomarkers is necessary for patient differential diagnosis and prognosis being IDH1, GFAP, Mki67, and MGMT the most reported ones. The inter-tumor molecular heterogeneity remains the hardest challenge in neuro-oncology practice. In our study, the expression profiles of those markers revealed a consistent link with the glioma progression model for tumor ontogenesis, supporting that GBM tumors display a unique behavior and that "personalized" treatment must be required for each molecular subtype. Our results suggest that a set of the following biomarkers ATRX, EGFR, H3F3A, MGMT, Mki67, NES, TP53, OLIG2 and VIM genes could be a strong combination to determine the GBM molecular subtype for patient prognosis. Notably, the frequency of mutations varies according to age group, highlighting the different mutational behavior of driver genes in the young subgroup. In particular, TP53 and EGFR, which show to be the most mutated genes in the adult and elderly subgroups, are not mutated in the young subgroup, in which ATRX is the most affected driver gene. Besides, a unique distribution of somatic mutations was found for the young and adult populations, particularly for genes related to DNA repair and chromatin remodeling ATRX, MGMT, and IDH1. We also highlighted differential patient age regulatory and biological pathway behaviors that could serve as a basis for further analysis in the journey of the development of improved therapy for patients suffering from this disease.

Acknowledgments: K.A.P thanks to the CABANA program for bioinformatics training. For technical support, we thank Luis Alberto Aguilar Bautista, Alejandro de León Cuevas, Carlos Sair Flores Bautista, and Jair García of the Laboratorio Nacional de Visualización Científica Avanzada (LAVIS).

Funding: This project was supported by CONACYT-SEP Investigación en Ciencia Básica grant 254206 and CONACYT grant 88344. K.A.P. received a postdoctoral fellowship from DGAPA-UNAM.

Conflict of interest: Authors declare no conflicts of interest.

FIGURES AND TABLES

- **Figure 1.** Comparison of driver gene expression profiles among patients grouped by GBM subtype.
- **Figure 2**. Distribution of the percentage of mutations in genes per chromosome observed in the TCGA-GBM project and the location of their mutations.
- **Figure 3**. Genome location and percentage of gene mutations according to patient age subgroup.
- **Figure 4.** Distribution of protein phenotype impact of mutation-consequences of driver genes grouped by patient age.
- **Figure 5.** Comparison of driver gene ontology enrichment analysis with the most lesioned genes in the TCGA-GBM project
- **Table 1.** Summary of selected clinical cases of GBM.
- **Table 2.** Summary of driver gene expression in GBM molecular subtypes with significant *p*-value.
- **Table 3**. Summary of driver gene expression in GBM molecular subtypes in the 10-29 year subgroup with significant *p*-value.
- **Table 4.** Summary of driver gene expression in GBM molecular subtypes in the 30-59 year subgroup with significant *p*-value.

Table 5. Summary of driver gene expression in GBM molecular subtypes in the 60-89 year subgroup with significant *p*-value.

Table 6. Summary of driver gene features with clinical relevance in GBM diagnosis.

Supplementary Figure 1. Distribution of GBM molecular subtypes across age groups.

Supplementary Figure 2. Frequence of mutations in the driver genes.

Supplementary Figure 3. Distribution of amino acid changes in proteins of selected driver genes.


Figure 4. Enrichment analysis of the most affected genes in polyphen impact grouped by patient age.


Supplemental File 1. PRISMA Statement of clinical report meta-analysis.


- 1. Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7-13.
- 2. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396-401.
- 3. Ohgaki H, Kleihues P. The definition of Primary and Secondary Glioblastoma. Clin Cancer Res. 2013; 19(4) 764-772.
- 4. Mansouri A, Karamchandani J, Das S. Molecular Genetics of Secondary Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU)2017.
- 5. Li R, Li H, Yan W, Yang P, Bao Z, Zhang C, et al. Genetic and clinical characteristics of primary and secondary glioblastoma are associated with differential molecular subtype distribution. Oncotarget. 2015;6(9):7318-24.
- 6. Han J, Puri RK. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor alpha1 and alpha2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol. 2018;136(3):463-74.
- 7. Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015;152:63-82.
- 8. Szopa W, Burley TA, Kramer-Marek G, Kaspera W. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. Biomed Res Int. 2017;2017:8013575.
- 9. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319-31.
- 10. Vizcaino MA, Shah S, Eberhart CG, Rodriguez FJ. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. Hum Pathol. 2015;46(9):1323-30.
- 11. Padfield E, Ellis HP, Kurian KM. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol. 2015;5:5.
- 12. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.


- 13. Sonoda Y. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Int J Clin Oncol. 2020;25(6):1004-9.
- 14. Aubry M, de Tayrac M, Etcheverry A, Clavreul A, Saikali S, Menei P, et al. From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget. 2015;6(14):12094-109.
- 15. Celiku O, Johnson S, Zhao S, Camphausen K, Shankavaram U. Visualizing molecular profiles of glioblastoma with GBM-BioDP. PLoS One. 2014;9(7):e101239.
- 16. Romero-Arias JR, Ramírez-Santiago G, Velasco-Hernández JX, Ohm L, Hernández-Rosales M. Model for breast cancer diversity and spatial heterogeneity. American Physical Society. 2018;98(3):032401.
- 17. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7 20.
- 18. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-13.
- 19. Kirstein A, Schmid TE, Combs SE. The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme. Cancers (Basel). 2020;12(5).
- 20. Marano D, Fioriniello S, Fiorillo F, Gibbons RJ, D'Esposito M, Della Ragione F. ATRX Contributes to MeCP2-Mediated Pericentric Heterochromatin Organization during Neural Differentiation. Int J Mol Sci. 2019;20(21).
- 21. Cantero D, Mollejo M, Sepulveda JM, D'Haene N, Gutierrez-Guaman MJ, Rodriguez de Lope A, et al. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv. 2020;2(1):vdz059.
- 22. Duan H, Hu JL, Chen ZH, Li JH, He ZQ, Wang ZN, et al. Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma. Chin Med J (Engl). 2020;133(12):1415-21.
- 23. Alexandru O, Horescu C, Sevastre AS, Cioc CE, Baloi C, Oprita A, et al. Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. Contemp Oncol (Pozn). 2020;24(1):55-66.
- 24. Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate Filaments as Effectors of Cancer Development and Metastasis: A Focus on Keratins, Vimentin, and Nestin. Cells. 2019;8(5).


- 25. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39-45.
- 26. Kosty J, Lu F, Kupp R, Mehta S, Lu QR. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas. Cell Cycle. 2017;16(18):1654-60.
- 27. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018;560(7717):243-7.
- 28. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672-88.
- 29. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420-7.
- 30. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458-68.
- 31. Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019;26(3):409-25.




















BIOMARKERS


ATRX, EGFR, H3F3A, MGMT, Mki67, NES, TP53, OLIG2, VIM




Age Group 80 - 89












Table 1.Summary of selected clinical cases of GBM.

				able 1.5umi	mary of selected	ciinicai cases	OI GDIVI.			
Reference	Database:	Gender:	Age₁	Symptoms ₁	Type of GBM tumor	Surgical Resection	Therapy,	Tumor Recurrence	Molecular Markers	Survival Time
Dormegny et al., 2018	BVS	Male	21	Hemiparesis, Seizures	Primary	N/A	N/A	Yes	H3K27M(+), IDH R132H(-)	3 Months
Kajitani T., et al, 2018	BVS	Male	13	Headache	Secondary	Partial	QT/RT, TMZ	Yes	GFAP(+),ATRX(+),VIMENTIN(+),TP53(+)MKi67(+),IDH-1 wt(+), H3KM27M(-),MGMT(-),BRAFV600E(-)	4 Months
									H3KM27M(-),MGMT(-),BRAFV600E(-)	
Kajitani T., et al, 2018	BVS	Female	16	Seizures	Secondary	Partial	QT/RT, TMZ	Yes	GFAP(+), ATRX(+), VIMENTIN(+), MKI67(+), IDH-1 wt (+), MGMT(-),	6 Months
									TP53(-), BRAFV600E(-),H3K27M(-)	
Kajitani T., et al, 2018	BVS	Female	16	Facial nerve	Secondary	Total	QT/RT, TMZ	No	GFAP(+), ATRX(+), TP53(+), VIMENTIN(+), MKi67(+), IDH-1 wt	Alive
				paralysis					(+)MGMT(-),BRAFV600E(-),H3K27M(-)	
Kumaria A., et al, 2018	BVS	Male	65	Headache, Personality	Primary	Total	N/A	Yes	IDH-1 wt (+), GFAP(+)	17 Months
				Disorder, Dizziness						
McClelland S., et al, 2018	BVS	Male	57	Headache, Hemiparesis	Primary	Partial	QT/RT, TTF	Yes	GFAP(+), VIMENTIN (+), TP53(+), IDH-1(+), MKi67(+)	25 Months
Petzold J., et al, 2018	BVS	Female	28	Headache,	Primary	Total	QT/RT	No	IDH-1 (+)	Alive
				Aphasia, Dizziness, Nausea						
Prelaj A., et al, 2018	BVS	Male	60	Aphasia, Hemioaresis	Primary	Total	QT/RT, TMZ	Yes	GFAP(+), EGFR(+), MKi67(+), TP53(+), IDH-1 wt(+)	6 Months
Ranjan S., et al, 2018	BVS	Female	51	Hemiparesis Headache,	Primary	Total	QT/RT,TMZ,	No	MKI67(+)	Alive
				Hemiparesis			Nivolumab			
Ranjan S., et al, 2018	BVS	Male	63	Aphasia	Primary	Total	QT/RT,TMZ, Nivolumab	No	MKi67(+)	Alive
Ranjan S., et al. 2018	BVS	Male	47	Headache, Nausea,	Primary	Total	QT/RT,TMZ,	Yes	MK67(+)	Alive
				Vomiting			Nivolumab, Ipilimumab			
Ranjan S., et al, 2018	BVS	Male	47	Headache, Aphasia	Primary	Total	QT/RT,TMZ,	Yes	MKi67(+)	Alive
Richard S.A., et al, 2018	BVS	Male	28	Seizures	Primary	Total	Nivolumab QT/RT,TMZ	No	GFAP(+), IDH-1(+), OLIG2(+), ATRX(+),TP53(+),	Alive
									MKi67(+),MGMT(+),TERT(+)	
Rosen J. et al., 2018	BVS	Female	48	Aphasia, Hemiparesis	Primary	Partial	QT/RT, TMZ, Bevacizumab	Yes	IDH-1 wt (+), MGMT(-)	13 Months
Wang Y., et al, 2018	BVS	Male	4	Headache,	Primary	Total	QT/RT,	Yes	GFAP(+),VIMENTIN(+),OLIG2(+), S-100(+)ATRX, TP53, IDH-1(+),	8 Years
				Hemiparesis, Vomiting			Bevacizumab, Nimotucimab,		SMAD3(+), SMARCB1(+), MGMT(+), MK967(+)	
Bärtschi P., et al. 2019	BVS	Male	44	Hemioaresis	Primary	Total by 5-ALA	Irinotecan QT/RT	No	S100A1(+), BRAFV500E(-)	Alive
	BVS	Male	44	Hemparesis	Primary	fluorescence	QI/RI	NO NO	S100A1(+), BRAFV600E(-)	Aave
Porto N., et al, 2019	BVS	Male	72	Headache	Primary	Partial by 5-ALA fluorescence	QT/RT	Yes	IDH-1 wt (+), ATRX(+)	5 Months
Awadalla AS et al., 2020	BVS	Male	60	Aphasia,	Primary	Partial	N/A	No	GFAP(+), VIMENTIN(+)	8 Months
Gestrich C et al 2020				Hemiplegia						
Gestrich C et al., 2020	BVS	Male	64	Altered mental status	Primary	Total	N/A	Yes	IDH-1 wt (+),GFAP(+), S1001A(+)	10 Months
Macchi ZA et al., 2020	BVS	Female	43	Seizures, Memory	Primary	N/A	QT/RT TMZ	No	IDH-1 wt (+)	9 Months
Watanabe N et al., 2020	BVS	Female	19	loss Headache	Secondary	Total	QT/RT TMZ	Yes	OLIG2(+),MKi67(+), BRAFV600E(+),ATRX(-),IDH1 R132H(-	Alive
),SMARCB1(-),H3F3A(-) H3K27M(-),TERT(-)	
Widjaja A et al., 2000	Karger	Male	58	Hemiparesis, Fever,	Primary	Total	QT/RT, Procarbacin	Yes	GFAP(+), VIMENTIN(+)	Alive
				Progressive confusion	,		, ,		1	
Hou LC et al, 2008	Karger	Female	30	Aphasia, Seizures	Primary	Partial	QT/RT TMZ	Yes	S-1001A(+),GFAP(+), VIMENTIN(+)	5 Months
E. Naydenov et al, 2009	Karger	Female	45	Headache.	Primary	Partial	QT/RT,TMZ	Yes	TP53(+), EGRF(+)	Alive
Roviello G., et al. 2013		Eom-1-	72	Hemiparesis Dizziness	Drie	Dow's I	QT/RT TMZ,	Yes	MKI67(+), EGFR(-), TP53(-)	4 Months
	Karger	Female			Primary	Partial	Corticostoroids			
Roviello G., et al, 2013	Karger	Male	76	Headache,Hemipar esis	Primary	Partial	Corticosteroids	No	MK67(+), EGFR(+), TP53(-)	5 Months
Elzinga G., et al, 2014	Karger	Female	76	Haminameir	Primary	Partial By CyberKnife	QT/RT, TMZ,	Yes	IDH-1(-),OLIG2(+),MGMT(+), EGFR(+)	22 Months
E. Naydenov et al, 2017				Aphasia, Confusion			Bevacizumab QT/RT			
E. Naydenov et al, 2017	Karger	Male	61	Aphasia, Hemiparesis	Secondary	Partial	QT/RT	Yes	MGMT(+)	Alive
Lewis GD., et al, 2017	Karger	Female	47	Headache, Nausea, Hemiparesis	Primary	Total	QT/RT, TMZ, IFN-β	Yes	GFAP(+), TP53(+),IDH-1 wt (+), MGMT(-)	5 Months
Papaevangelou G., et al, 2017	Karger	Female	7	Hemiparesis Physic	Primary	Total	QT/RT, Temodal.	Yes	GFAP(+),S-100(+), EGFR(+), SMARCB1(+), VIMENTIN(+), OLIG2(+),	20 Months
				al disability	,		Erlotinib		GFAP(+),S-100(+), EGFR(+), SMARCB1(+), VIMENTIN(+), OLIG2(+), H3K27M(+),MKi67(+), SMA(-), TP53(-)	
Hasan S., et al, 2018	Karger	Female	58	Hemiparesis	Secondary	Total	QT/RT	No	IDH-1 wt (+), MKi67 (+), MGMT(-)	Alive
Van Seggelen W., et al., 2019	Karger	Male	62	Ataxia	Primary	Total	QT/RT TMZ,	Yes	IDH-1 wt (+), MGMT(+)	Alive
Thummalapalli R et al., 2020	Karger	Male	74	Aphasia	Primary	Partial	Nivolumab QT/RT, TMZ,	Yes	BRAFV600E(+), IDH-1 wt(+), MGMT(-)	14 Months
	Karger	man		Apriasia	rimaly	Pattal	Nivolumab	res		14 Months
Rajagopalan V et al., 2005	Pubmed	Male	60	Headache, Hemioaresis	Primary	Partial	QT/RT TMZ, Irinotegan.	Yes	GFAP(+)	21 Months
							Celecoxib			
Zhang C., et al, 2010	PubMed	Male	17	Dysphagia, Hypokinesia	Primary	Partial	QT TMZ	Yes	GFAP(+), S100A1(+), VIMENTIN(+), TP53(+), MGMT(-), EGFR(-)MKi67(-)	37 Months
Zuccoli G, et al. 2010	PubMed	Female	65	Headache, Nausea,	Primary	Partial	QT/RT TMZ	Yes	MGMT(+)	Alive
				Memory Loss			Irinotecan, Bevacizumab			
Miao-Xia He et al,2011	PubMed	Male	31	Headache	Primary	Total	QT/RT	Yes	GFAP(+),SMARCB1(+),SMAD3(+), S100A1(+), TP53(+)Vimentin(+),MKi67(+)	4 Months
Paraskevopoulos D et al., 2011	PubMed	Female	12	Hemiparesis,	Primary	Total	QT/RT Vincristine,	Yes	GFAP(+), S100A1(+),MKi67(+),	12 Months
				Dysesthesia	,		Etoposide, Carboolatin			
Jeong T.S., et al, 2014	PubMed	Male	32	Headache	Primary	Total	QT/RT TMZ	No	GFAP(+), MKi67(+), EGFR(-), MGMT(-)	Alive
Lakičević G et al., 2014	Pubmed	Male	53	Headaches,	Primary	Total	QT/RT TMZ	No	GFAP(+)	Alive
Matsuda M et al., 2014	Pubmed	Male	69	Nausea, Vomiting Facial Pain	Primary	Partial	QT/RT TMZ	No	GFAP (+), MKI67(+), EGFR(+), TP53(-), IDH-1 R132H (-)	Alive
Theeler BJ et al., 2014	PubMed	Female	36	Progressive neurologic deficits	Secondary	N/A	QT/RT TMZ	Yes	IDH1 wt R132H(+), BRAFV600E(+)	Alive
Theeler BJ et al., 2014	PubMed	Male	32	Progressive	Primary	Partial	QT/RT TMZ,	Yes	IDH wt R132H(+), PIK3CA(+)	Alive
				neurologic deficits			Erlotinb			
Johnson DR., et al, 2015	PubMed	Male	73	Hemiparesis, Seizures	Primary	Total	QT/RT TMZ	Yes	MGMT(+)	24 Months
Woo PYM., et al, 2015	PubMed	Female	22	Headache	Primary	Total	RT, Dabrafenib, Trametinib	Yes	MGMT(+), BRAFV600E(+), IDH-1 wt(+)	7 Months
Woo PYM., et al, 2015	PubMed	Male	22	Headache	Primary	Partial	BRAFI,	Yes	IDH-1 wt(+), MGMT(+), BRAFV600E(+), TERT(+), EGFR(-)	8 Months
					,		Vemurafenib, Cobimetinib.			
							Palpociclib			
Johansen MD et al., 2016	PubMed	Female	59	Headache, Blurred visión	Primary	Total	QT/RT TMZ, Bevacizumab	No	GFAP(+),TP53(+),OLIG2(+), MGMT(+), MKi67(+), ATRX(+), IDH-1(-)	8 Months
Johansen MD et al., 2016	PubMed	Male	60	Seizures Cerebral	Primary	Total	N/A	No	GFAP(+), OLIG2(+),MKi67(+), MGMT(+), IDH-1(-), ATRX(-), TP53(-)	10 Months
Elena A et al., 2016	PubMed	Male	43	hemorragia Headache	Primary	Total	RT/QT, TMZ,	Yes	GFAP (+), VIMENTIN (+), MGMT(-), EGFR(-)	25 Months
	1 domed		45	Theadache	,	TO ME	Bevacizumab	163	GIAL (1) VINERIUS (1) MONTO, EGITO)	25 11011013
Elena A et al., 2016	PubMed	Male	30	Seizures	Primary	Total	QT/RT, TMZ, Bevacizumab	Yes	GFAP(+),VIMENTIN(+),EGFR(-), MGMT(-), IDH-1 (-),	6 Years
Chen F., et al, 2017	PubMed	Female	5	Fever, Vomiting	Primary	Total	N/A	Yes	MGMT(+), S100A1(+), GFAP(+), TP53(+),MKi67(+), IDH-1 wt(-)	2 Months
Gandhi P., et al. 2017	PubMed	Female	45	Aphasia	Primary	Partial	QT/RT	Yes	TP53(+), EGFR(+), TERT(+), MKi67(+), IDH-1 wt (-)	26 Months
Efferth T et al., 2017	PubMed	Male	65	Headache,	Primary	Partial	QT/RT TMZ	No.	MGMT(+)	Alive
Shen CX., et al, 2017 Tokuda Y., et al, 2017	PubMed PubMed	Female Male	15 27	Hemiparesis Seizures,	Primary Secondary	Partial Total	QT/RT, TMZ	No Yes	GFAP(+), MKI67(+) MKI67(+), VEGFR/FLT1 (+), IDH-1 Mutant(+)	13 Months Alive
				Headache			Bevacizumab			
Wang L., et al, 2017	PubMed	Female	50	Headache, Hemiparesis,	Primary	Total	RT	No	VIMENTIN(+), GFAP(+), OLIG2,(+), TP53(+), BRAFV600E(+), NESTIN(+), IDH1-R132H(-)	Alive
				Nausea, Vomiting						
Wang L., et al, 2017	PubMed	Male	36	Headache, Nausea, Vomiting	Primary	Total	QT/RT, TMZ	Yes	VIMENTIN(+), GFAP(+), OLIG2(+), BRAFV600E(+), NESTIN(+), IDH1- R132H(-), TP53(-)	8 Months
Zhang H.,et al., 2017	D.A.	100			B-0		DT			
znang H.,et al, 2017	PubMed	Male	40	Headache, Hemiparesis,	Primary	Total	RT, TMZ	Yes	KI-67(+), TP53(+), MGMT(-)	Alive
Zhou K., et al, 2017	PubMed	Male	31	Vomiting	Primary	Total	QT/RT, TMZ	Yes	GFAP(+),VIMENTIN(+),NESTIN(+), EGFR(+), OLIG2(+),MKI67(+)	15 Months
				Headache, Vomiting						
Comito R., et al 2019	PubMed	Female	57	Headache, Nausea, Photopsia	Primary	Total	QT/RT, TMZ,	Yes	MKi67(+), GFAP(+), MGMT(+), IDH-1 w(-)	5 Months
				1			Lomustina, Nivolumab		<u> </u>	
Finneran M., et al , 2019	PubMed	Female	29	Aphasia, Cefalea, Confusion	Secondary	Total	RT	No	GFAP(+),TP53(+),IDH-1-wt (-),BRAFV600E(-),MGMT(-),EGFR(-),SMARCB1(-),S-100(-)	Alive
Homma T. et al, 2019	PubMed	Female	78	Speech difficulty and Forgetfulness	Primary	Partial	QT/RT, TMZ	No	S-100A1(+),GFAP(+), OLIG2(+), ATRX(+), SMARCB1(+), MK967(+), BRAFV600E(-), IDH-1-R132H(-)	Alive
Janik K., et al., 2019	PubMed	Male			Driv.	Total	QT/RT, TMZ			23 Months
Janux K., et al., 2019	PubMed	ntale	51	Headache, Memory Loss	Primary	rotal	UI/KF, TMZ	Yes	GFAP(+), MKi67(+), TP53(+), BRAFV600E(+),IDH-1 wt (+),EGFR(+)	23 Months
Narasimhaiah D., et al, 2019	PubMed	Male	16	Headache, Vomiting, Dyplopia	Primary	Partial	QT/RT	Yes	S-100A1(+),GFAP(+), TP53(+), MKi67(+), IDH-1(-), ATRX(-)	Alive
Narasimhaiah D., et al, 2019	PubMed	Female	21	Headache	Primary	Total	QT/RT	No	GFAP(+), TP53(+), MKi67(+), S100(+),ATRX(-),IDH-1 R132H-mutant(-	Alive
				Seizures)	
Nerexe DS., et al , 2019	PubMed	Male	62	Confusion, Aphasia	Primary	Partial	QT/RT, Bevacizumab,	Yes	IDH-1 wt(+), ATRX(-), MGMT(-)	15 Months
Nerexe DS., et al , 2019	D.A.	100	30	l llead of	Free :	De	Irinotecan QT/RT, TMZ		CERTA PRINTS ATTIVAL AND TO	4216 "
	PubMed	Male		Headache, Seizures, Confusion	Secondary	Partial		Yes	GFAP(+), IDH-1(+), ATRX(+), MGMT(+)	12 Months
Chanchotisation A et al., 2019	PubMed	Female	27	Hemiparesis, Dysuria	Primary	Partial	QT/RT, TMZ	No	GFAP(+),MKi67(+),OLIG2(+),ATRX(+),H3K27M(+),Nestin(+),	Alive
Cuoco JA et al., 2019	PubMed	Male	76	Hemiparesis,	Primary	Partial	QT/RT	No	MGMT(+), IDH-1 wt (+),EGFR(-), TP53(-)	1 Months
				clumnsiness						
Romo CG et al. 2019	PubMed	Male	28	Headache, Nausea, Personality	Primary	Total	QT/RT, TMZ, VPC	Yes	GFAP(+), OLIG2(+),ATRX(+), IDH-1 mutant(+), TP53 mutant(+),MGMT(+), S100(+), SMARCB1(+), H3KM27(-)	3 Months
Honor A. et al. 2019	PubMed	Ermah	20	changes, Aphasia	Briss.	*	2014	V		1 Month
Uppar A., et al, 2019 Sajan A., et al, 2020	PubMed PubMed	Female Female	28 39	Hemiparesis Headache	Primary Primary	Total N/A	N/A QT/RT TMZ	Yes No	GFAP(+),H3K27M(+) MKi67(+), IDH-1(-) GFAP(+), EGFR(+), IDH-1exon 4 mutated (+), MGMT(+), H3K27M(+),	1 Month Alive
									BRAFV600E(-)	
Gupta S., et al, 2020	PubMed	Male	58	Seizures	Primary	Total by 5-ALA fluorescence	QT/RT	Yes	IDH-1 wt R132H (+)	Alive

	NE	PRON	ΙEU	JRAL	CLAS	SSI	CAL	MESENCHYMA				
DNA Repair and Chromatin remodeling genes												
ATRX	-0.176	±	0.761	0.37	±	0.936	0.084	±	0.601	-0.213	±	0.591
BRAF	-0.378	±	0.378	-0.152	±	0.495	-0.237	±	0.563	0.056	±	0.468
H3F3A	-0.038	±	0.548	0.34	±	0.572	-0.079	±	0.613	-0.495	±	0.606
MGMT	0.716	±	1.716	-0.128	±	1.237	-0.078	±	1.464	0.614	±	1.268
TERT	0.099	±	0.422	0.148	±	0.385	0.26	±	0.482	0.156	±	0.49
Cytoskeleton and celular proliferation genes												
EGFR	0.865	±	3.77	-3.494	±	3.78	3.502	±	4.36	-2.002	±	3.787
FLT1	-0.824	±	1.06	-0.571	±	0.813	-0.301	±	1.023	0.082	±	1.093
GFAP	0.233	±	0.664	0.114	±	0.87	0.367	±	0.493	-0.293	±	1.037
IDH1	0.224	±	0.715	-0.175	±	0.881	0.484	±	1.089	-0.168	±	0.872
MKI67	-1.072	±	1.292	1.019	±	1.545	-0.114	±	1.269	-0.325	±	1.005
NES	-0.745	±	1.025	-0.032	±	0.852	1.525	±	1.004	0.053	±	0.909
OLIG2	-0.052	±	1.051	1.316	±	1.182	0.07	±	1.173	-1.455	±	0.964
PIK3CA	-0.92	±	0.595	0.241	±	1.043	-0.178	±	0.924	-0.146	±	0.763
S100A1	1.628	±	1.559	0.52	±	1.218	-0.723	±	1.063	-0.013	±	1.464
SMAD3	0.108	±	0.400	-0.234	±	0.711	0.3	±	0.425	0.261	±	0.579
VIM	-0.836	±	0.889	-0.602	±	1.134	0.805	±	0.973	0.671	±	0.878
Tumor supressor genes												
SMARCB1	0.023	±	0.944	0.934	±	0.884	0.425	±	1.005	-0.393	±	0.893
TP53	-0.002	±	0.949	0.101	±	1.026	0.703	±	0.813	0.074	±	0.775

YOUNG SUBGROUP (10-29 years)	PRONEURAL	CLASSICAL							
DNA Repair and Chromatin									
remodeling genes									
ATRX	0.105 ± 1.316	-0.105 ± 0.711							
BRAF	0.257 ± 0.466	0.034 ± 0.777							
H3F3A	0.375 ± 0.626	-0.202 ± 0.619							
MGMT	0.297 ± 0.494	0.176 ± 1.782							
TERT	0.066 ± 0.335	0.196 ± 0.464							
Cytoskeleton and celular proliferation genes									
EGFR	-3.133 ± 1.228	-4.563 ± 2.382							
FLT1	-0.946 ± 0.61	-0.955 ± 0.539							
GFAP	-0.106 ± 0.914	0.262 ± 0.113							
IDH1	-0.679 ± -0.679	-0.910 ± 0.204							
MKI67	0.820 ± 2.157	0.572 ± 1.801							
NES	-0.207 ± 1.018	0.822 ± 1.167							
OLIG2	0.998 ± 1.427	-1.341 * ± 0.859							
PIK3CA	0.058 ± 0.526	0.272 ± 0.844							
S100A1	0.452 ± 1.032	0.101 ± 0.807							
SMAD3	0.104 ± 0.732	0.664 ± 0.438							
VIM	-1.127 ± 1.343	1.455 * ± 0.353							
Tumor supressor genes									
SMARCB1	0.830 ± 0.653	0.653 ± 0.874							
TP53	0.286 ± 0.993	-0.336 ± 1.242							

ADULT SUBGROUP (30-59 years)	NEURAL			PRONE	RAL	CLASS	AL	MESENCHYMAL				
DNA Repair and Chromatin remodeling genes												
ATRX	-0.230	±	0.904	0.279*	±	0.920	0.113*	±	0.608	-0.180	±	0.583
BRAF	-0.339	±	0.381	-0.125			-0.122	±	0.561	0.064*	±	0.505
H3F3A	-0.092	±	0.575	0.375 **	±	0.446	-0.121	±	0.609	-0.451*	±	0.602
MGMT	0.696	±	1.686	-0.354	±	1.236	0.200	±	1.339	0.786	±	1.272
TERT	0.108	±	0.413	0.099	±	0.402	0.357	±	0.472	0.138	±	0.451
Cytoskeleton and celular proliferation genes												
EGFR	0.516	±	4.050	-2.693*	±	3.863	3.314*	±	4.265	-1.970	±	3.678
FLT1	-0.808	±	1.085	-0.637	±	0.735	-0.259	±	1.091	0.194*	±	1.220
GFAP	0.119	±	0.663	0.055	±	1.018		±	0.541	-0.399	±	1.054
IDH1	0.125	±	0.586	-0.054	±	0.833	0.781**	±	1.065	-0.115	±	0.889
MKI67	-1.094	±	1.453	1.065 ***	±	1.551		±	1.278	-0.061*	±	0.938
NES	-0.913	±	1.170	-0.198*	±	0.700	1.380**			-0.151*	±	0.941
OLIG2	0.098	±	0.786	ماد ماد ماد	±	1.021		±		-1.581***	±	1.063
PIK3CA	-1.073	±	0.550	0.415 ***	±	1.229	-0.370**	±		-0.328**	±	0.625
S100A1	1.289	±	1.270	0.467*	±	1.287	alaskala	±		0.127**	±	1.516
SMAD3	0.166	±	0.463	-0.207	±	0.838		±			±	0.542
VIM	-0.929	±	0.927	-0.369	±	1.083	0.564***	±	0.850	0.778***	±	0.944
Tumor supressor genes												
SMARCB1	0.171	±	0.902	1.008*	±	0.951	0.311	±	0.998	-0.297	±	0.862
TP53	-0.087	±	0.992	0.194	±	1.162	0.829**	±	0.654	-0.124	±	0.809

ELDERLY SUBGROUP (60-89 years)	NEURAL			PRONEURAL			CLASS	AL	MESENCHYMAL			
DNA Repair and Chromatin												
remodeling genes												
ATRX	-0.121	±	0.579	0.557***	±	0.718	0.077	±	0.557	-0.255	±	0.597
BRAF	-0.417	±	0.372	-0.331	±	0.498	-0.474	±	0.408	0.047 **	±	0.416
H3F3A	0.015	±	0.513	0.293*	±	0.649	0.014			-0.551***	±	0.606
MGMT				-0.07	±	1.377	-0.57*			0.394	±	1.230
TERT	0.09	±	0.431	0.226			0.121	±	0.463	0.178	±	0.535
Cytoskeleton and celular proliferation genes												
EGFR	1.214	±	3.432	-4.398***	±	4.122	5.495 ***	±	2.32	-2.045 [*]	±	3.921
FLT1				-0.368			-0.229			-0.062	±	0.884
GFAP	0.346	±	0.645	0.253	±	0.647	0.575	±	0.382	-0.157	±	0.997
IDH1	0.323	±	0.812	-0.103	±	0.916	0.307	±	0.966	-0.237 *	±	0.844
MKI67	-1.049	±	1.106	1.05 ***	±	1.226	-0.356			-0.663	±	0.987
NES				0.193**	±	0.864	1.904 ***	±	1.004	0.314**	±	0.792
OLIG2				1.36**			0.524			-1.293 **	±	0.792
PIK3CA				0.143**	±	0.968	0.03*			0.086 **	±	0.855
S100A1				0.596**			-0.973 ***	±	1.2	-0.192 **	±	1.373
SMAD3				-0.387**			0.269	±		0.341	±	0.614
VIM	-0.744	±	0.838	-0.629	±	1.021	1.048***	±	1.111	0.535 ***	±	0.764
Tumor supressor genes												
SMARCB1	-0.126	±	0.962	0.901**	±	0.886	0.602*	±	1.016	-0.515	±	0.916
TP53				-0.058	±	0.864	0.724	±	0.767	0.327	±	0.645

Table 6. Summary of driver gene features with clinical relevance in GBM diagnosis.

				gene reatures with clinical relevance in GB	
DNA repair and chromatin remodelling	Gene description	Clinical function.	Biological Relevance.	Regulation and prevalence in GBM.	Meta-analysis summarized findings.
					1973 district cases used \$TRY expression as a himselver for nations area ranging from 4.78 years did 11/17 shown differential expression of this name
	ATRX in Xq21.1 is a chromatin				Expression profile: Highly variant in each subtype, nevertheles no significant changes among GBM subtypes. Mutations: ATRX presents a significant number of
	remodeling protein HELICASE 2, X-	Presence of mutations in this gene is associated with a poor prognosis. Tumors that express this gene are more aggressive and grow at a faster rate. Predictive marker	Main function is the deposition of the histone H3 variant but also affect	Downregulated (-) In grade II-III astrocytomas (71%), oligoastrocytomas (68%) and	mulsions (56 in total) in all patent ages, where consequences are varied, but the most abundant are missense varient and downstream gene varient. The first is
ATRX	X-LINKED NUCLEAR PROTEIN GENE	Tumors that express this gene are more aggressive and grow at a faster rate.	other cellular functions related to epigenetic regulation and participates	secondary glioblastomas (57%) mutations are widely distributed in the glioma and correlate	was known to produce an amino acid crininge and treetone a dissense prosent in conformation. As as ages, accessores are present, nowever, inservors are only present in this adult supproup, and deletions in this subgroup and in the young subgroup. However, in dead vital status of the young subgroup, there are no
	ATRX in Xq21.1 is a chromatin remodeling protein.HELICASE 2, X- LINKED; XH2 X-LINKED NUCLEAR PROTEIN GENE XNP, encodes a putative NTP-binding nuclear protein homologous to serveral	Predictive marker	Main function is the deposition of the histone H3 variant but also affect ofter cellular functions related to epigenetic regulation and participalitis in the regulation of the cell cycle, cellular proliferation and maintain genome stability.	Downsegulated (-) In grade II-III saltrocytomas (71%), oligosatrocytomas (85%) and secondary globinatomas (57%) mutations are widely distributed in the gloma and correlate with an increase in the mutation rate at the SNP level, various changes in the DNA methylation pattern, as well as selectome dysfunction.	1972 dated cases and 20% careasism in a binomic for plates again early fee of? Ye are 44.1177 bean different discovering of this spee. From our posted by 1972 we will be a set of the production as explicit of speed and speed of the production of the speed of t
	members of the helicase II superfamily.				пристем при на п
					HSF3A mutation HSK27M was measured in 8/73 clinical cases as a biomerker for young patients (7-59 years). The diagnosis of glioblastoma with histone H3.3
		The H3K27M mutation has been highly linked to pediatric thalarric giornas. The substitution of a lysine for methionine at position 27 in histone H3 nasulting in an H4K27M mutation in the most commonly found mutation and is associated with a worse prognosis than love-grade tumors.		Upregulated(*) 20-30% of GBM Most usual in pediatrics, adolescents and young adults, is associated with poor prognosis	The Section of Section 1 is also installed in CVI confeder classes as a comment or young passes (in 1-2) years, the suppress on groups agreement of the section of the sect
	H3 HISTONE, FAMILY 3A; H3F3A 1q42.12, Histone responsible for the nucleosome structure of the chromosomal fiber.	The substitution of a lysine for methionine at position 27 in histone H3	Whip and compact DNA into chromatin, limiting DNA accessibility. Play a certral role in transcription regulation, DNA repair, DNA replication and chromosomal stability.	20-30% of GBM Most usual in pediatrics, adolescents and young adults, is associated with poor prognosis.	Expression profile: Highy variant in each subtype, with a tendency to down-regulation in the measurchymal subtype. In the TCGA database, this game reported
H3F3A	nucleosome structure of the	resulting in an H3K27M mutation is the most commonly found mutation and is	a central role in transcription regulation, DNA repair, DNA replication	regardiess - 17.9%.ansplastic astrocytoma ganglioglicena or Diffuse glormas	only a substitutions, it in the young subgroup and it in the actur subgroup. I make the insulators and as consequence a massesse variant producing the USSN and CSSN arringed charged at a subgroup and use of the control of the contr
	chromosomal fiber.			- 17.9% anaplastic astrocytoma manninglings or Diffuse glomas	
					EST as its most clear becomes for 1995 Engineers. 4517 distinct areas reported resourced to post mustice RTSUF Engineers cells (highly session and multiples, with the equipolation insteading or the occasional unitples, 1995 or throwed only on management in the pumping and extrapolations are the admitted of the management of the extrapolation and the
	ISOCITRATE DEHYDROGENASE, NADP(+).IDH1 2q34 is a dimeric cytosolic NADP-dependent isocitrate		Despite its tumorogenic potential, its mutation is associated with greater overall survival, secondary GBM or young patients. Mutation catalyzes the production of 2-HG, leading to DNA hypermethylation and eventually	Hosen-late-d(a)	the adult subgroup, all of them substitutions. The consequences of these mutations are missense variant, downstream gene variant and non-coding transcript
IDH1	NADP(+).IDH1 2q34 is a dimeric	Biomarker of secondary multiple glioblastoms and a poor prognosis for the	overall survival, secondary GBM or young patients. Mutation catalyzes	Upregulated (*) 4n 80% cases of secondary GMB and white it is very rare in primary GBM -Common in proneural subtype and secondary tempura	exon variant, being the first one the most abudent. However, this consequences had mainly a negative polyphen impact in the adult subgroup with vital status dead, although few had same impact in the other subproups.
	dehydrogenase.		gliomagenesis	-Common in proneural subtype and seccondary tumours	
					31/73 clinical cases used MGMT expression/promoter methylation as a biomarker for patients 4-76 years old. In the clinical cases examined all eldery patients
		MCMT methylation increases sensitivity to one of the most commonly used			1973 direct cases used MEMI expression/promote methylation as a bromater for patients 4-79 years old. In the clinical cases examined all oldery patients by low any oil pensylate of positive methylates. Because of the clinical cases examined all olders patients. Expression profiles frighty varient in each substipes, with any operapidation involvery in the mean and necession/profile intelligence and any other profiles on patients of the profiles profiles of the p
	MGMT 10q26.3 encodes an enzyme tha	t alkylating agents for GBM, terrozolomide (TMZ). Hypermethylated MGMT is a	MGMT promoter methylation predicts sensitivity to TMZ treatment. Highly	Upregulated (+) - Unmethylated promoter - 64% in primary GBM; 25% in secondary GBM.	Only 1 substitution was reported in the young subgroup which produces a non-coding transcript varient. Four substitutions were found in the adult subgroup
MGMT	MGMT 10q26.3 encodes an enzyme that acts as a O(6)-methylguanine-DNA methyltransferase.	potent predictor of the response to treatment with alkyteting agents and can also be a positive prognostic factor for patients with GBM. Patients expressing	MGMT promoter methylation predicts sensitivity to TMZ treatment. Highly conserved and involved in DNA repair, aliminating the alkyl adducts of the O ^S position of the guarrine at the DNA level.	Upregulated (+) - Unmethylated promoter - 64% in primary GBM; 25% in secondary GBM. MCRIT protects the cells from carcinogenesis and also from the lethal effect of chemotherapy with alkylating agents.	producing missense variants and non-coding transcript variants. The polyphen impact had negative consequences only in the subgroup with vital status alive, and nonline in the vital status dates.
		MCANT methylation increases sensitivity to one of the most commonly used it allysising agains for CBM, temcosterride (1MC2), Hypermethylated MCANT is a power power power of the response to treatment with subject against an extra lable be a positive prognosic factor for patients with CBM. Patients expressing this gene have higher services response.			
					2/73 clinical cases used TERTpromoter mutation, patients were 22 and 28 years old. Both showed positive results. Expression profile: Holdy variant in each subtyoes, nevertheles no significant chances among QBM subtyoes.
	TELOMERASE CATALYTIC SUBUNIT;	TERT has been associated as a molecular marker of noor	Telomerase is an enzyme whose mechanism of action consists of the addition of nucleotides to billomeras. Involved in oncogenesis	Upregulated(+)	TERT presents a total of 17 mutations, having no significant difference among different ages. These mutations are all substitutions whose most abundant
TERT	TCS1 EST2TERT is a gene located on chromosome 5p 15.33 and encodes the catalytic subunit of letomenase.	TERT has been associated as a molecular marker of poor prognosis even worse than IDH-1 since TERT confers resistance to TMZ, which is the primary	- Modulates Wht signaling	~80-80 in GBM and oligodendrogliomas In some CBM it is measurepresent which revises a constant renair of the nells and inhibits.	\$27.0 cm class see TRT (Former's realism, patient, was 22 and 28 pers out, that the strengt patient realism. Unpressure profess they waster near-shaped presentations are considered any patient and shapes. TRT presents about 017 mileston, however, or specificated difference serving different less. These manadators are of substitutions whose most about dark unpressure and the strength of the st
	chromosome 5p15.33 and encodes the catalytic subunit of telemerar-	chemotherspeutic adjuvant.	Modulates Whit signaling It plays important roles in oall aging and anti-epoptosis. Associated with aggressive turnors.	In some GBM it is over-expressed which causes a constant repair of the cells and inhibits apoptosis so that the tumor becomes aggressive	
Protein of cytoskeleton and cellular					
proliferation					BBAE (APAC) matrice was compared in 1879 sliping error patients was 19 74
					prun: (vouc) museson was examined in 16/73 clinical cases, patients were 13-78 years old. Wang et al 2017 reported two clinical cases were this mutation was used as a differential biomarker for Glosarcomas (a variant of GSM) diagnosis.
	ONCOGENE BRAF	I buildly associated with an annessing nhanotune and is a few seconds		8% to 7% of primary tumors of the central nervous system (CNS), but with a higher	Expression profile: Highly variant in each subtype, nevertheles no significant changes among GBM subtypes.
BRAF	BNAP1 7q34.BRAF is a protein kinase and part of the MAP kinase singular	Usually associated with an aggressive phenotype and is a key prognostic biomarker for a poor prognosis. However, turnors that express this mutation are candidates for a chemotherapy treatment directed at BRAFV600E.	-Protein that plays a role in regulating the MAP kinase / ERK signaling pathway, which affects cell division, differentiation, and secretion.	prevalence in the pediatric population and in certain subtypes of brain tumors. An active mutation of the access point occurs in V600E and results in constitutive MAPS constitution.	difference among age subgroups. Missense variant is the most abundant consequence of these mutations, and downstream gene variant, stop gain, S-UTR
	ONCOGENE BRAF BRAF1 7q34 BRAF is a protein kinase and part of the MAP kinase signaling cascade	are candidates for a chemotherapy treatment directed at BRAFV600E.	, and the second s	8% to 7% of primary tumors of the central nervous system (CNS), but with a higher prevalence in the pediatric population and in certain subhypes of brain tumors. An active matation of the access point occurs in V600E and results in constitutive MAPK signaling and uncontrolled cell growth.	BMF (1600) nation was earnined in 1973 climat came, palents were 13-78 years off. Wing et al 2017 reported too climat came were the mutation Expression perfect. Fighty waired in each subject, recorded are supplied and perfect of larges armong QBM subject. The parties of the supplied in the result in the resul
					18/73 clinical cases evaluated EGFR amplification and R776C mutation as a propositic biomarker. Patients were 7-76 years old. EGFR was used as a
					biomarker since the first clinical cases reported (2009). EGFR amplification is considered the most common and shared genetic variant among GBM patients,
					1972 distinct cases evaluate EGPR emplification and RYTNC modifics as a proposable binameter. Preliment were 7.78 years out 6.60°CR years used as a formarier winner first dirtical cases reported (2009), EGPR emplification is considered the most common and shared genetic variety among CBM parients, besides BHT mostation. Evaluation of the most common and shared genetic variety among CBM parients, besides BHT mostation. Evaluation in the most common and shared genetic variety and often deposit on the contraction of the con
	ONCOGENE ERBB ERBB1 7p11.2 HER1.The epidermal growth factor receptor (EGFR) has a tyrosine kinase activity.	Despite being an indication of aggressive turnors, also makes it a cardidate for flexapsusfor harapies Blased on monoclosal antibodies directed to EGPR secth as Bevaricaments or Cataments which function binds to the related EGPR ligands by regulating it negatively.	The ECCO Materian modifies the DNA of COM cells the	Upregulated (+) - Mulaint form (EGFRviti) present with amplified wild-type EGFR - In 44-50% cases of GBM, mostly primary and classical GBM or other present of the control	belows LPC induction. The description of the description of the second and description in the second and description shadpers, and down-regulation in the promotion of the second and description shadpers. ECRR as one of the desire general with more multidaria, having found the in text. Distriction, desired and extractions are description of the second and descriptions, which has provided produces on the second produces on the second produces of the second and descriptions, and the second produces on the second produces on the second produces of the second and descriptions of the second produces of the second pro
EGFR	HER1.The epidermal growth factor	for therapeutic therapies Based on monoclonal antibodies directed to EGFR both as Repair towards or Cataginah which function hinds to the problem ECFR	RAS/PI3K, FOXG1 or SOX9 pathways and has been associated with a	often overexpressed in aggressive tumors such as GBM. It is known that overexpression	curry is one or my convergenes with more mutations, having found 89 in total. Substitutions, deletions and insertions were found in the adult and elderly subgroups, while the young subgroup only reported substitutions, being these the most frequence at all ages. The missense variant is by far the most abundant.
	receptor (EGFR) has a tyrosine kinase	ligands by regulating it negatively.	high degree of malignancy and poor response to treatment.	and activation of EGFR have a significant impact on the distinctive features of cancer cells, burth as increased cell survival proliferation and invasion.	consequence, increasing with age. Moreover, the young subgroup only presents 4 types of consequences, while the adult and elderly subgroup 10 different
				and the same of th	this gene had no mutations.
		-			A side of the same
					2 clinical cases reported FLT1 as a biomarker. A clinical case of a male patient of 27 years old reported FLT1 NECFR expression as a diagnosis biomarker. The identification of this designated molecule had implications for Bevacioumsb monoclonal antibody treatment.
					identification of this designated molecule had implications for Bewardszinnish monoclonal antibody teatment. Expression positio, Highly variant in each subptps, with a down-regulation tendency in the neural subptps. One insertion was found in R.T.1 in the adult subproup and 16 substitutions distributed in all subgroups, being reliatively more abudant in the adult and elderly subgroups. Missingers variant is the most abundant consequences, increasing anginificantly the sumber of consequences types in the adult subgroup. A negative
		Early prognostic marker and may aid in the clinical management of patients	Binds vascular endothelial growth factor (VEQF)-A, VEQF-B, and PIQF.	Upregulated (+) - In 30% cases of GBM, mostly primary and classical GBM.Contribute to the	One insertion was found in PLTI in the adult subgroup and 16 substitutions distributed in all subgroups, being relatively more abudant in the adult and elderly subproups. Missense variant is the most abundant consequence, increasing alignificantly unpresequence buses in the adult subproup. A negative
FLT1:VEGFR	FACTOR RECEPTOR 1: VEGFR1/FLT-	Early prognostic marker and may aid in the clinical management of patients with glorns. Patients with low-grade FLT-1 positive astrocytoms have a significantly shorter overall median survival time than those with FLT-1 negative surrors.	is a positive regulator of angiogenesis and vasculogenesis that contributes to cell survival, proliferation, cancer migration and invasion	Upregulated (+) - In 30% cases of GBM, mostly primary and classical CBM.Contribute to the pathogenesis of cancer by promoting inflammatory responses and the recruitment of tumor- infiltrating macrophices.	polyphen impact is reported in patients with vital status dead in all subgroups, however this is also the case in the adult subgroup with vital status alive.
	13q12.3 is tyrosine protein kinase	negative tumora.	and tumor metastases	infiltrating macrophages	
					42/73 clinical cases evaluated GFAP protein expression in patients from 4 to 78 years old. It was the second most frequently used biomarker frequently using impress/histonishinal statistics.
		Blood OFAP values are used to assess the size, aggressiveness of the tumor land is associated with necrois, edema, and tumor recurrence. These characteristics make it an efficient florester for the prognosis and appropriate therapy. The high levels of expression of this protein are correlated with the degree of tumor maligrampy.	An intermediate Comment matrix that projections the extent electron of		immunohistoquimical staining.
	Glial fibrillary acidic protein17q21.31, (GFAP)that is highly specific for cells of	and is associated with necrosis, edema, and tumor recurrence. These	An infarmediate filament protein that maintains the cytoskeleton of mature astrocytes. GFAP has a significant effect on various astrocyte properties, such as mosphology, growth, and cell division. This protein is released into the bloodstream in case of acute brain tissue damage and		Expression profile: Highly variant in each subtype, nevertheles no significant changes among GBM subtypes, classical subtype showed a slight tendency to up- regulation.
GFAP	(GFAP)that is highly specific for cells of astroglial lineage.	characteristics make it an efficient biomarker for the prognosis and	properties, such as morphology, growth, and cell division. This protein is	Upregulated (+) -In 75% cases of GBM, mostly primary and classical GBM	In the TCGA database, only one mutation was reported in gene GFAP, this was a substitution that appeared in the elderly subgroup. However, this single
	ana ogran innsage.	correlated with the degree of tumor malignancy.	astroglial necrosis.		Immunolatiopsterial attempts of the polymers o
					2017 Zindoli came and McIII experience is a Limenta's for printing representation 4.1 My printing for a significant point of the printing representation of the representation o
		K67 is a marker of cell profileration and serves to provide a clinical prognosis because the timor growth rate is quartified with M67 - antibodies. The shades are provided to the control of the control			Ordy few matterors were present in the young subgroup in Molity, and increase proportionally to the number of patients in the adult and eidenly subgroups,
	ATRX Chromatin Remodeler, MKI67	because the tumor growth rate is quantified with MB-1 antibodies. The			reporting one deletion in the adult age. As in other driver genes, the most common consequence is the missense variant in all age subgroups. At young age,
Mont	ATRX Chromatin Remodeler MKI67 10q26.2 is a 359-kD nuclear protein commonly used to detect and quantify protferating cells, with increased	faster the cells are dividing so that the tumor grows faster, thus giving a lousy	Birds DNA, with a preference for supercoiled DNA and AT-rich DNA. Play a role in chromatin organization and cellular proliferation, associated with the degree of malignancy of the tumor.	Overexpression(+)	impact is mostly reported in the aduld and elderly subgroup with vital status dead, however few mutations in the subgroups with vital status alive also report a
MNO)	proliferating cells, with increased	prognosis, as it is considered as an aggressive tumor. Although in some	associated with the degree of malignancy of the tumor.	80-70% of GBM	negative polyphen impact.
	expression associated with cell growth	chemotherapy, which help to indicate that the patient is a good candidate for			
		this type of therapy			
					473 driving cases used MSS expression to evaluate terms bropy tissue from patients of 77.59 years of the patients of 27.59 years of 27.59
	Nestin 1g23.1. is an intermediate	Biomarker of proliferating and migrating cells and the multidifferentiated	Expressed in proliferating cells during the developmental stages and is involved in the organization of the cytoskeleton, cell signaling.	Upregulated (+)	Only few substitutions were found in this gene at all ages. Mutations in NES produced missense variants in all cases, with the exception of one synonymous
NEC	filament protein (IF) expressed	Siomarker of proliferating and migrating cells and the multidifferentiated characteristics of multiple lineage progenitor cells. Proliferation Marker. Play a d role in Neural Stem Cell Differentiation Pathways and Lineage-specific	involved in the organization of the cytoskeleton, cell signaling, organogenesis, cell metabolism. Required for survival, renewal and mitogen-atimulated proliferation of neural progenitor cells	Upregulated (+) Common in anaplastic astrocytome (WHO grade III) and GBM. Nestine can be expressed under pathological conditions and has been detected in high concentrations in	variant. Very lew mutations reported a negative polyphen impact and only in the eliderly subgroup with vital status dead, all other subgroups reported a positive includes in immact as included in mutations in this name.
NES	predominantly in stem cells of the central nervous system in the neural tube.	d role in Neural Stem Cell Differentiation Pathways and Lineage-specific	mitogen-stimulated proliferation of neural progenitor cells	under pathological conditions and has been detected in high concentrations in	росурати первол ве ресолосто и из полевони и и из приводи.
		Markers		Glioblastomas, relating it to a worse prognosis for patients.	
	OLIG2 is a basic halix-loop-halix (bHLH 21g22.11 transcription factor essential fo		High expression in astrocytomas, oligodendroglomas and oligoaxinoptomas, collectively referred to as diffuse gliomas, conferring on frem the ability to self-respensatio and replicate in an exponential marrier. Regulator of weetan insurroctodermal progenitor cell fate and realised in pathways like Neural Creat Differentiation, Neural Stem Cell Differentiation and Linsage-specifs Marker.		19/73 clinical cases evaluated CLIG2 as a biomerker for GBM diagnosis on patients from 4-78 years. The reoptastic cells were positive for Clig2 protein in all clinical cases reported.
OLIG2	21q22.11 transcription factor essential fo) Blomarker of diffuse gliomss and given their expression, a tumor prognosis of and evaluation can be made to make a correct therapeutic decision - Differentiation biomarker	on them the ability to self-regenerate and replicate in an exponential	Ovensynession(+) 5-10% in Anaplastic oligodendroglioma (grade III) Common in GBM	Expression profile: Highly variant in each subtype, with a tendency to up-regulation in the proneural subtype and a down-regulation in the mesenchymal subtype.
	oligodendrocyte and motoneuron development in the spinal cord	Differentiation biomarker	manner, regulator of ventral neuroectodermal progenitor cell fate and related in pathways like Neural Crest Differentiation, Neural Stem Cell	Common in GBM	Circuit Class reported. Chickles Reported. C
			Differentiation and Lineage-specific Marker.		mutation reported a negative polyphen impact in patients with vital status dead.
					mulation reported a registrie polyphin impact in patients with visit states dead. If "20 clinical cases and \$500 / As as biometrie perfecting spar register 4.5" by sear old. This filament protein supregulation was positive in 151/14 cases. Expression polific highly varient in each subplye, with an up-equilation in head on the completion in the disserties and down engalation in the disserties and down engalation in the disserties and the search and the
	S100A1 1q21.3 Calcium Binding Protein	One of the most important molecular markers that reveal demage in the certain nervous system furnor marker in the diagnosis and monitoring of GBM parkers. Survey 1500 values rise most significantly in patients with survey before sociality beatment with OT, RT or ratiosurgery and these values are normalize with for exportes to thespies.	Involved in the negulation of a number of cellular representation of the		Only two mutations were found in \$100A1, one of them a substitution in the young subgroup and one deletion in the adult subgroup. No mutation in this gene
SIDDAI	A1 function in calcium-dependent regulation of cell cycle progression, differentiation, and chemotaxis.	central nervous system.tumor marker in the diagnosis and monitoring of GBM netarnts Serum \$100 values rise more significantly in netarnts with trans-	Involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. This protein may function in stimulation of Ca2+ release, inhibition of microtubule assembly, and inhibition of protein hinase C-mediated phosphorylation	Overexpression(+) ~ 65-80%. Very common in GBM. Protein S100 helps in monitoring the disease, since its concentration decreases with effective treatments and rises when the disease progresses	was sound in the eigenty subgroup. The deletion caused a trainestrift variant, and both mutations caused non-coding transcript exon variant. Moreover, the substitution had two more consequence types: downstream gene variants and STUTR variants. No polyphen impact information was found for metalines in this
S.OURT	regulation of cell cycle progression, differentiation, and chemotexis	before receiving treatment with QT, RT or radiosurgery and these values are	stimutation of Ca2+ induced Ca2+ release, inhibition of microtubule assembly, and inhibition of protein kinese C-mediated phosphorylation	concentration decreases with effective treatments and rises when the disease progresses	gene.
		normasus with the response to therapies.	, and a second second		
					16/73 clinical cases used VIM expression as a biomarker for patient prognosis. Patients were 4 to 60 years old All patients shown positive results for this
					16773 clinical cases used VM expression as a biomarker for patient prognosis. Patients were 4 to 60 years old All patients shown positive results for this biomarker.
		Rinmarker since nations with CRM and with two commonion of a	Intermediate flament protein, responsible for maintaining cell shape, surport and interrity of the cytodesm, and stabilizing cytodestal	I Insurantiated (+) . High laught in CRM regulief (company and block homes one ""	Expression profile: Highly variant in each subtype, with a marked tendency to down-regulation in the neural and proneural subtypes, and to up-regulation in the
VIM	VIM 10p13Vimentin (intermediate filament family).	Biomarker since, patients with GBM and with low expression of vimentin have a better response to the treatment of RT, QT and improvement if TMZ is added, in addition to a longer survival. Prognostic biomarker	support and integrity of the cytoplasm, and stabilizing cytoskeletal interactions. Maintains cellular integrity and participates in several cell signal pethways to modulate the motility and invasion of cancer cells.	Upregulated (+) -High levels in GBM predict low survival and high tumor proliferation, depending on the expression rate the type of tumor can be diagnosed and predict tumor	Two mutation were found in VIM, a substitution in the young subgroup with vital status alive and another one in the adult subgroup with vital status dead. No
	Tanana anny).	ladded, in addition to a longer survival. Prognostic biomarker	signal pathways to modulate the motility and invasion of cancer cells. Vimentin is the subunit specific for mesenchymal tissue	development	16/73 distinct cases used VM expression as a biometer for palent-propries. Plants were 4 to 90 years of Alf pathers show posters results for this Segmental profits. 16/93 certain in each subject, with an entered bendering to done-regulation in the result and promote subspace, and to up-equilation in the classical and researchystal subspace. The models were born of VM, as absolition in the promp subpropulation between the profit of the properties of the profit of the prof
					при
					Theefer et al 2014 presented a clinical report of five clinical cases to evaluate tumor recurrence and Bevacizumab treatment. Patient were diagnosed with
					Their et al. 2414 passets a clinical report of the clinical cases to evaluate timer recurrence and indexestation between the Section S
	PHOSPHATEDYLINOSITOL 3-KINASE, CATALYTIC, 110-KD, ALPHA p110-ALPHA PISK-ALPHA PIKS-ALPHA 3428-32. Phosphoinositid		Activates signaling cascades in cancer involved in cell growth, survival,		nevertheles no significant changes among GBM subtypes. 41 mutations were found in PKSCA, being mostly substitutions but 3 deletions in the adult subgroup.
PIK3CA	p110-ALPHA	Mutations have preferably been found in young patients and have been	proliferation, motify and morphology. This gene has been found to be oncoonic and has been implicated in a number of cancer trans-	Overexpression(+) -10-15% de GBM with missense mutations -Mutation associated with the most aggressive	I he number or muserons are proportional to the number of patient in each subgroup. As in other driver genes, the most frequent consequence of mutations in this gene is the missense variant. Most of the mutations were found in the subgroups with vital status dead, but all of them reported a nevertice involved.
FIRSUA	PISK-ALPHA	associated with a decrease in patient survival.	Interacts with AKT and mTOR pathways signaling promotes cell growth	type of cancer	However, no mutations in this gene were found in the young subgroup with vital status dead.
	PIK3-ALPHA 3q26.32. Phosphoinositid 3-Kinase	7	Activates signaling cascades in cancer involved in cell growth, survival, profilestion, mostly and morphology. This gene has been found to be onoughnic and that been implicated in a number of cancer types transact with ACT and TOR pathways agreeting promotes cell growth and survival and is other activated in infiliative glicoms.		
					3/73 clinical cases of young patients (4,7,31 years old) examined SMAD3 expression as a biomarker for GBM diagnosis coupled with other molecules
					Jur 3 cirrical cases or young piesents (+,7,31 years old) examined SMAD3 expression as a biomarker for GBM diagnosis coupled with other molecules evaluations.
	SMAD FAMILY MEMBER 3: SMAD3	Prognostic biomarker. The SMAD3 protein plays a role in the TGF- β signaling	SMAD3 is a direct mediator of transcriptional activation by the YOF-hera		Expression profile: Highly variant in each subtype, nevertheles no significant changes among GBM subtypes. One substitution was found in each see subcroup in cere SMADS. The missenne variant is the most abustent consequence in young and adult subcroups.
SMAD3	SMAD FAMILY MEMBER 3; SMAD3 15q22:33 intracellular signal transduce protein	Prognostic biomarker. The SMAD3 protein plays a role in the TGF-B signaling pathway, regulating gene excivity and cell proliferation, also acting set a tumor suppressor. It is a promising therapeutic target for the treatment of GBM The mutation results in profiferative, invasive and resistants of behavior.	SMADS is a direct mediator of transcriptional activation by the TGF-beta receptor. Its target genes in epithelial calls include cyclin-dependent kinase inhibitors that generate a cytostatic response.	Downregulated(-)~60-70% in GBM	exitations better highly varies in early subject, exceptions or significant charges among GBM subjects. On substitution was bond in earth gas largering in gene SMADA, in missaries waiter in the most absolute consequence in young and adult subgroups, housew, this consequence does not already on the substitution and the most absolute consequence of the mustations in this consequence does not already only in the absolute propriet on graphs only only the mustation in this supera subgroups with the absolute propriet on graphs only only the mustation in the surger subgroups with the absolute propriet on graphs only only the mustation in the surger subgroups with the absolute propriet on graphs only only the mustation in the surger subgroup with the absolute propriet on graphs only only the mustation in the surger subgroup with the absolute propriet or graphs only only the propriet or graphs or graphs or graphs.
	protein	mutation results in proliferative, invasive and metastatic behavior.	xorsase intribitors that generate a cytostatic response.		gene. Only the mutation in the young subgroup with vital status allive reported a negative polyphen impact.
Protein acting as tumor repressors					
			L		2072 Total came reduced randoms in 1502 passins for 600 patients disposed. Parents even 4.75 years dit. We bord their chrisis classes highested to consider the consideration of
			Protein containing transcriptional activation, DNA binding, and oligomerization domains - The mutated game does not perform its	Downrequisited (-)	Expression profile: Highly variant in each subtype, with an up-regulation tendency in the classical subtype.
	TUMOR PROTEIN p53 17p13.1. Tumor		functions as cell cycle arrest, apoptosis, senescence, DNA repair, or	-Mutanta present in 90% of secondary GBM; 67% in proneural subtype -Their expression	This gene was the most abundant in mutations at all ages, having a total of 118, being mostly substitutions. However, deletions and insertions were also present
TP53	suppressor and transcription factor	Biomarker that correlates with a worse prognosis.	changes in metabolism -play critical roles in preventing tumors by organizing a wide variety of cellular resonance including demand and	Downsegulated (-) -Mutanta present in 90% of secondary GBM, 67% in proneural subtype -Their expression correlates with verse prognosis -Mutations in the p53 gene have been linked in the irression of GBM calls, migration, proliferation, evasion of apoptosis and maturity of cancer value.	status dead. All types of consequences were the product of this mutations, being the synonymous variant the only one that was not caused by mutations in this
			Protein containing similariporana activador, UNA centraling, and oligomenication domaina—The matelad grain does not perform la functions as cell cycle arreat, apoptosis, senascience, DNA requisit, or champes in matelablamin—play rollicat roles in preventing hurrors by organizing a wide variety of cell trian responsess, including claimaged cell apoptosis, maintenance of genomic stability, inhibition of angio-genesia and regulation of cell matelabolism and the turnor microenvironment.	cells.	gene. Most of the mutations reported a negative polyphen impact.
			and regulation of cell metabolism and the tumor microenvironment.		
					773 clinical cases reported this home suppressor problem expression as a biomarker. Pulletin weres 4.75 years old. 774 clinical cases reported this home suppressor problem expression and the second control of the co
	The CHARGES ST		But of a secondary that prisoner many	Description () 40 700 in ORM and are	Expression profile: Highly variant in each subtype, with an up-regulation landency in the proneural and classical subtypes. No multifors were found in the young subgroup in SMARCB1, and only 2 substitutions in the adult subvivious and one in the adult's subvivious and subvivious and one in the adult's subvivious and the
GMADCD1	a subunit of the SWISNF ATP-dependen	s t. Biomarker of poor prognosis because patients presenting with the loss of the a INI-1 gene are associated with a decrease in helf of their life expectancy	Part of a complex that relieves repressive chromatin structures This protein is involved in transcriptional regulation and a tumor suppressor and its mutations in it have been associated with malignant Rhabdoid tumors normally developed in children.	Downsegulated(-) = 60-70% in GBM and meningiomae = 80% in schwannomae NI1 is a constitutely expressed rucker protein whose function and role appear to be impaired through the p16-Rb E2F and p53 dependent pathways. Tumors that express mutations or deletions of the IN1 gene SM relabeloid tumors.	insertion, all of them with vital status dead. As in other driver genes, the most frequent consequence was the misserise variant. All mutations reported a negative
G.MAROD1	chromatin-remodeling complex. NI-1 is tumor suppressor name	a INI-1 gene are associated with a decrease in half of their life expectancy	and its mutations in it have been associated with malignant Rhabdoid fumors normally developed in children	through the p16-Rb E2F and p53 dependent pathways. Tumors that express mutations or ideletions of the INI1 came SM rhabboid tumors.	росурствен опривод.
	musu andreases Aspe		, arrespectively.	and the same of th	
Table Description				l .	I